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6  Summary 
The recommendation of artemisinin-based combination therapy (ACT) as a first 
line treatment of malaria continues to be based only on data obtained from single 
episode treatment rather than repetitive treatment. However, malaria episodes are 
frequent and there is thus a need to understand the long-term impact of repeated use 
of ACT to treat consecutive episodes of malaria over successive seasons.  My study 
aimed to define the risk of parasite recurrence as a function of the pharmacokinetic 
and pharmacodynamic characteristics of ACT partner drugs in patients re-treated for 
multiple malaria episodes. Participants from Mali were randomized into three 
treatment arms: dihydroartemisinin-piperaquine (DHA-PPQ), pyronaridine-artesunate 
(PA), and first-line ACT (either artemether-lumefantrine [AL] or artesunate-
amodiaquine [ASAQ]). Participants received the same ACT for each new episode of 
malaria for two years.  Clinical and parasitological data were collected at each visit. 
Plasma samples were collected at day 7 of follow-up for quantification of drugs using 
high-performance liquid chromatography methods. In total, study participants 
experienced 5,260 episodes of malaria during the two-year follow-up period. Major 
findings were: i) accumulation of desethylamodiaquine (DEAQ), the main and active 
metabolite of amodiaquine (AQ), in the study population after early (between 25 to 45 
days) retreatment with ASAQ; ii) no association of DEAQ concentration on day 7 
with treatment outcome; iii) an association between day 7 lumefantrine concentrations 
and a reduced risk of re-infections within day 28 follow-up (hazard ratio, HR = 0.605, 
CI (0.50 – 0.74), p < 0.001). This protection of lumefantrine was concentration 
dependent; a concentration below a threshold of 380 ng/ml did not protect against 
subsequent re-infection by day 28. Importantly, the majority of the children under five 
years (84 out of 140; 60%) had lumefantrine day 7 concentrations (median 
(interquartile range): 305 ng/ml (207 – 490 ng/ml)) below this threshold.  In 
conclusion, my results demonstrated an accumulation of DEAQ in the study 
population after early re-treatment with ASAQ, and suggest a need of lumefantrine 
dose optimisation in under five years age group. My analyses also showcase the value 
of re-treatment studies for improving treatment recommendations. 
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7 Zusammenfassung 
Die Empfehlungen für die Artemisinin-basierten Kombinationstherapien 
(artemisinin-based combinations, ACT) basieren nach wie vor auf Daten von 
einzelnen Malariaepisoden. Jedoch sind Malariaepisoden häufig und ein besseres 
Verständnis von wiederholten Behandlungen auf Wirksamkeit und Nebenwirkungen 
ist wünschenswert. Meine Analyse zielte daher auf eine Definition des Risikos von 
Reinfektionen als Funktion der pharmakokinetischen und pharmakodynamischen 
Eigenschaften von ACT Partnerwirkstoffen in Patienten mit multiplen 
Malariaepisoden ab. Patienten mit unkomplizierter P. falciparum Malaria (>6 
Monate) von Mali wurden in drei Behandlungsarme randomisiert: 
Dihydroartemisinin-Piperaquine (DHA-PPQ), Pyronaridin-Artesunat (PA) und eines 
der beiden gegenwärtigen Frontline ACT (entweder Artemether-Lumefantrin (AL) 
oder Artesunat-Amodiaquin (ASAQ). Studienteilnehmer erhielten die gleiche ACT 
für jede neue Malariaepisode über 2 Jahre. Blutproben vom Tag 7 nach Beginn einer 
Behandlung wurden für die Bestimmung von Plasmakonzentrationen mittels High-
Performance Liquid Chromatography verwendet. Insgesamt wurden 5.260 
Malariaepisoden registriert. Meine wichtigsten Ergebnisse sind: 1) Akkumulation von 
Desethylamodiaquin (DEAQ), dem Hauptmetaboliten von Amodiaquin (AQ), in der 
Studienpopulation nach früher (25-45 Tage) Neubehandlung mit ASAQ; 2) keine 
Assoziation von DEAQ Konzentration am Tag 7 mit der Zeit bis zur nächsten 
Infektion; 3) Tag 7 Konzentration von Lumefantrin korrelierte negativ mit dem Risiko 
von Reinfektionen bis Tag 28 (hazard ratio, HR = 0.60; CI, 0.50-0.74; p<0.001). 
Dieser Schutz war abhängig von der Konzentration von Lumefantrin; eine 
Konzentration unter 380 ng/ml schützte nicht vor Reinfektionen bis Tag 28. 
Insbesondere Kinder unter 5 Jahren (84 von 140; 60%) zeigten Tag 7 Lumefantrin 
Konzentration unter diesem Schwellenwert: Median von 305 ng/ml (interquartile 
range, 207-4.900 ng/ml). In Zusammenfassung, meine Ergebnisse zeigen eine 
Akkumulation von DEAQ in der Studienpopulation bei früher Neubehandlung mit 
ASAQ und legen eine Optimierung der Dosierung von Lumefantrin in Kindern unter 
5 Jahren nahe. Meine Analysen unterstreichen auch den Wert von Studien mit 
wiederholten Behandlungen für verbesserte Behandlungsempfehlungen. 
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1 Introduction 
1.1 Malaria epidemiology and distribution: 
Malaria is a parasitic disease transmitted to human and other animals by 
infected female Anopheles mosquito’s bites. Malaria can also rarely be transmitted 
through blood transfusion, and intrauterine transmission from mother to child 
(congenital malaria). Human malaria is caused by protozoan parasites of the genus 
Plasmodium. Plasmodium falciparum (Pf), P. malariae (Pm), P. ovale (Po) (curtisi 
and wallikeri), P. vivax (Pv), and P. knowlesi are the species that are known to cause 
human malaria. Of these six species, Pf and Pv are the most prevalent accounting for 
more than 95% of malaria cases worldwide. In 2016 the World Health Organization 
(WHO) estimated that Pf accounted for 99% of malaria cases in sub-Saharan Africa. 
Pv was the most dominant in the WHO region of the Americas, responsible for 64% 
of malaria cases, and more than 30% of recorded cases in the WHO South-East Asia 
and 40% in the Eastern Mediterranean regions [1].  
In Mali, which is part of the WHO defined region of sub-Saharan Africa, 
except for P. knowlesi, all five human malaria species are encountered. Pf is the 
dominant parasite species with a prevalence fluctuating between 63.7 to 99% [2, 3]. 
Pv is present in north and north-eastern Mali and its prevalence can reach 30% in 
some locations [3, 4]. The presence of Pv is also described in central Mali in Duffy 
antigen negative people with a prevalence of 2 to 2.5% [5].  
Malaria transmission is seasonal in Mali.  The low transmission period 
coincides with the dry season (January to May), with an incidence rate of malaria 
infection close to zero, but this period is characterized by persistent infections. The 
high transmission period begins with the start of the rainy season in June and lasts 
until December. Peak incidence of malaria infection occurs at the end of the rainy 
season (between September and October) [6, 7]. 
Despite an 18% global reduction in number of cases of malaria between 2000 
and 2016 (from 76 to 63 cases per 1,000 persons at risk [1]), malaria infection 
remains a critical public health challenge.  The estimated annual number of malaria 
cases in 2016 was 216 million, with 445,000 deaths due to malaria, of which 91% 
occurred in the sub-Saharan region of Africa [1].  Children under five years 
represented 7 out of 10 cases of death due to malaria [8]. 
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In the sub-Saharan region of Africa, a report by Bhatt et al. in 2015 estimated 
that from 2000 to 2015 malaria incidence rate (case per 1,000 per annum) declined 
from 321 to 192 cases [9]. Another report by Gething et al. in 2016 showed a drop in 
malaria mortality from 12.5 to 5.5 cases (per 10,000 population per year) during the 
same period [10]. The reduction in malaria mortality observed across all sub-Saharan 
Africa was less pronounced in Mali where the incidence rate dropped only from 
around 490 to 463 cases from 2000 to 2015 [9], while malaria mortality fell from 
around 32 to 23 cases during the same period [10]. 
In malaria endemic countries, particularly in Pf endemic countries, patients 
can suffer more than 10 episodes of clinical malaria per year [11], resulting in 
frequent use of antimalarial drugs.  The development of partial immunity can occur 
after repeat exposure to infection.  A naturally acquired immunity (premunition) can 
protect against severe malaria and later, also against mild malaria but never fully 
protects against infection [12, 13]. The key challenge for controlling or eventually, 
eliminating malaria, particularly Pf malaria, is the capacity of the parasite to evade 
sterilising immunity and to cause life-long re-infections.  
The life-threatening character of Pf malaria has exerted a strong selective 
pressure on the malaria-exposed population. This has given rise to 
haemoglobinopathies, which can provide almost full protection against severe malaria 
but at the same time can cause disabling conditions with significantly reduced life 
expectancies [14, 15]. The most prominent example of haemoglobinopathy is sickle 
cell or haemoglobin S (HbS), a well-studied structural variant of the β-globin chain of 
haemoglobin (substitution of glutamic acid with valine at position 6). HbS is frequent 
in malaria-exposed populations with allele frequencies of up to 30% [15, 16], despite 
the debilitating consequence of its homozygote form [17]. Carriers of homozygote 
and heterozygote forms of HbS are protected against severe malaria [18, 19] with a 
10-fold reduction of risk [20]. Another mutation at the same position (replacement of 
glutamic acid by lysine) of the same hbb gene, called HbC, does not cause debilitating 
conditions, but also protects against severe malaria whether in homozygote or 
heterozygote form [21, 22]. HbC is more frequent in West Africa and is a 
characteristic of the Dogon people, an ethic group in Mali, from severe malaria [21]. 
Haemoglobin E (substitution of glutamic acid with lysine at position 26) is another 
variant of β-globin chain. It is a common variant in Southeast Asia, and is assumed to 
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protect against invasion of erythrocytes by Pf [23]. Other genetic variants in the 
human host which are protective against malaria and involve modifications to 
erythrocyte biology include: G6PD deficiency [24-26], α-thalassemia [27, 28], 
ovalocytosis [29, 30], Duffy-negative blood group [31] and glycophorins [32, 33].      
 
1.2 Clinical manifestations of malaria 
Human malaria infection is a potentially life-threatening disease characterised 
by fever and other unspecific symptoms. Following the bite of an infected mosquito, 
the first symptoms appear in the human host after 7 to 30 days (incubation period), 
and are caused by the erythrocytic schizogony in the blood. During the erythrocytic 
stage, malaria parasites consume and degrade host haemoglobin to produce hemozoin 
pigment waste. This hemozoin pigment and other malaria toxins like 
glycosylphosphatidylinositol (GPI) moieties are dumped into the blood stream during 
schizont rupture and merozoite release from infected red blood cells. These induce the 
synthesis and release of tumour necrosis factor and others cytokines like interleukin-1 
(IL-1), IL-6, IL-12, interferon-gamma and soluble factors like nitric oxide 
intermediates and reactive oxygen intermediates, resulting in chills, fever and other 
symptoms associated with malaria infection [34-37].  
Depending on symptoms, malaria can be classified as uncomplicated or 
complicated. Uncomplicated Pf malaria is defined by WHO as symptomatic Pf 
malaria parasitaemia without signs of severity or evidence of vital organ dysfunction 
[38]. The clinical manifestations of uncomplicated Pf malaria are usually: fever or 
history of fever, chills, headache, body aches, dizziness, vertigo, altered behaviour, 
weakness, nausea, vomiting, diarrhea, jaundice, hepatosplenomegaly. Patients can 
often be found with different combinations of the cited symptoms above.   
Complicated (severe) Pf malaria is defined by WHO as an acute falciparum 
malaria with signs of severe illness and/or evidence of vital organ dysfunction. The 
more common symptoms found in the patients with complicated Pf malaria are: 
hyperparasitaemia; where the parasite count is higher than 500,000 per microliter of 
blood, hyperpyrexia; where the temperature is higher than 40˚C, hypotension, 
hypoglycaemia, severe aneamia; where the haemoglobin level is under 5 g per 
decilitre, jaundice, generalized convulsions, impaired consciousness, coma, metabolic 
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acidosis, acute respiratory distress syndrome, pulmonary oedema, acute kidney 
failure, and disseminated intravascular coagulation [39, 40].  
Pf is responsible for the majority of severe malaria cases. But, it has also been 
reported in patients with Pv malaria, where except for hyperparasitaemia, the clinical 
manifestations of Pv versus Pf severe malaria are the same including symptoms of 
severe anaemia, acute respiratory distress [41], and acute kidney failure [42]. Severe 
knowlesi malaria also has been described.  Here symptoms similar to those of Pf 
malaria are typical with two differences, being hyperparasitaemia, which for severe 
knowlesi malaria is defined as a parasite density higher than 100,000 per microliter, 
and jaundice, characterised by a parasite density higher than 20,000 per microliter 
[39]. The other two species infecting human (malariae and ovale) rarely cause severe 
malaria. 
1.3 Malaria biology and life cycle 
Plasmodium spp. are single-celled eukaryotic protozoan parasites. They have a 
complex life-cycle which alternates between an invertebrate (female Anopheles 
mosquitoes) and a human host.  
Infected mosquitoes carrying malaria sporozoites in their salivary gland, 
during a blood meal, deposit them into the skin of the human host. At this stage, a 
large proportion of sporozoites remain in the skin and are eliminated. Others travel to 
the lymph nodes, where some are engulfed and degraded in dendritic leucocytes, and 
some can partially differentiate into exoerythrocytic stages before destruction [43-45]. 
The remaining sporozoites glide to enter the dermal capillaries and are drained by 
blood flow into the liver. In the liver, they are arrested by binding to the sinusoidal 
cell layer, where they glide and pass through the Kupffer cells.  They traverse several 
hepatocytes, killing them, before settling in one for differentiation and multiplication 
[43-45]. The thrombospondin-related anonymous protein (TRAP), a protein which is 
expressed on the surface of sporozoites, is indispensable for gliding motility [46]. 
TRAP and other major surface proteins of sporozoites including the circumsporozoite 
protein are implicated in sporozoites binding to the sinusoidal cell layer of 
hepatocytes [45]. In hepatocytes, the parasites develop inside a parasitophorous 
vacuole (PV), the formation of which is induced by sporozoites during the process of 
invasion [47]. Sporozoites replicate asexually to form schizonts (a multinucleate stage 
of the parasite), and then several thousand of merozoites (the parasite stage that can 
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invade and infect red blood cells). After hepatocyte infection Pv and Po sporozoites 
can enter a latent, non-replicative state called hypnozoites [48]. These dormant 
hypnozoites can resume growth and complete liver-stage development, and then cause 
relapsing blood-stage infection months to years after the initial infection, in the 
absence of a new infective mosquito bite. The last step of the hepatic stage of parasite 
infection is egress from hepatocytes. Rupture of the PV membrane releases 
merozoites inside the hepatocytes cytoplasm followed by initiation of host cell 
detachment and death [49]. During this process of detachment and death vesicles 
filled with merozoites, known as merosomes, bud into the sinusoid lumen [50]. To 
avoid detection by the host immune system the parasites manipulate the hepatocyte 
and inhibit the exposure of phosphatidylserine on the outer leaflet of plasma 
membranes [50]. The merosomes migrate and deliver merozoites directly into the 
bloodstream.  
Very few antimalarial drugs are active on the hepatic forms of the parasite, 
particularly the latent hypnozoites. The main antimalarial drugs active on hypnozoites 
are primaquine and tafenoquine [51-53]. 
Merozoites are the smallest cell of the Plasmodium life cycle. They have all 
the conventional organelles of eukaryotic cells, including a nucleus, mitochondrion, 
Golgi apparatus, endoplasmic reticulum, and an inner membrane complex underlying 
the plasma membrane, sub-pellicular microtubules, and an apicoplast. Micronemes, 
rhoptries and dense granules constitute the apical complex of secretory organelles.   
The merozoite stage is immunologically important. It is the stage where the parasites 
are briefly extracellular and exposed to host antibodies between egress and new 
invasion.  Released merozoites invade red blood cells and start the erythrocytic cycle. 
During the invasion process the initial interaction involves deformation of the 
erythrocyte after attachment of merozoites to the cell surface. Some studies suggested 
the implication of merozoites surface protein 1 (MSP-1) and other surface proteins in 
this attachment [54, 55]. The initial attachment is followed by apical reorientation, 
bringing into contact the apical pole with the erythrocyte surface. At this stage, the 
parasite is irreversibly attached to the cell surface and is ready for invasion [56]. The 
parasites move inside the red blood cells under the action of an actomyosin motor and 
the formation of a tight junction between parasite and erythrocyte plasma membranes 
[57, 58]. The tight junctions are established using apical membrane antigen1 
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(AMA1), a microneme derived protein associated with the parasite membrane and 
rhoptry neck (RON) complex of proteins; a rhoptry derived protein anchored into the 
red blood cell [59]. As the merozoites move inside, the PV and membrane are formed 
from rhoptries and cell membrane components. The last step of invasion is 
echinocytosis of the red blood cell, after which the parasites are free and mobile in the 
cells [60].   
In the infected erythrocyte, parasite asexual development is complex, and 
passes through a succession of three morphological stages, being ring, trophozoite and 
schizont. At the end of the erythrocytic cycle, the rupture of the schizont leads to the 
release of 16 to 32 daughter merozoites, which can enter new red blood cells to start 
the cycle again. Parasites develop inside the parasitophorous vacuolar membrane 
(PVM). For the survival inside the erythrocytes, parasites modify the host cell through 
the export of proteins. The majority of parasite proteins are exported during the ring 
stage of development [61]. The trophozoite stage is characterised by rapid growth of 
the parasites and the appearance of haemozoin (malaria pigment) a bio-crystal 
remnant of haemoglobin digestion [62]. Many antimalarial drugs interfere with this 
bio-crystallisation of haems to haemozoin. Free haems are toxic for malaria parasites. 
Pf is detectable by microscopy in the blood stream only in the first half of its 
erythrocytic cycle. During the second half, trophozoites and schizonts are sequestered 
in the deep vasculature [63], a principal cause of morbidity and mortality induced by 
malaria [64]. Parasite proteins, including Pf erythrocyte membrane protein 1 
(PfEMP1), expressed on the surface of host cell are involved in the sequestration and 
parasite virulence [65-67]. These Pf proteins are believed to be trafficked to the host 
cells surface trough parasite-induced vesicular structures named Maurer’s clefts [62, 
68]. The display of these Pf proteins, necessary for the sequestration of infected 
erythrocytes, is facilitated by host cell surface structures named knobs [69].  
In addition to parasite multiplication, the blood-stage parasite asexual 
replication results in the generation of the sexual stage, the gametocytes. The 
commitment of the asexual form to sexual development starts at some point in the 
preceding schizogony [70]. The asexual schizont committed for gametocytogenesis 
releases merozoites which invade new red blood cells and develop through the 
trophozoite stage to produce gametocytes [70]. Each dedicated schizont produces 
progeny of only one sex: either male or female gametocytes [70]. The maturation of 
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gametocytes passes through five stages. Only stage I, the early one and stage V, the 
mature one, are found in the blood circulation. Stages II – IV sequester in the bone 
marrow, and are absent from the blood circulation [71]. Many factors have been 
associated with increased gametocyte production including administration of the 
antimalarial drug chloroquine. Other antimalarial drugs, such as the 
8-aminoquinoleine primaquine, have gametocytocidal activity [72].  
The pre-erythrocytic phase lasts for around 5 – 7 days for Pf, 9 - 10 days for 
Pv, 9 days for Po, 13 days for Pm and 8 – 9 days for P. knowlesi [73]. Antimalarial 
drugs with a short half-life which do not have any action on pre-erythrocytic parasite 
stages cannot protect patients against rapid new infection.   
Most of the available antimalarial drugs act on the erythrocyte stage of the 
parasite’s life cycle (Figure 1). This stage takes around 24 hours to be completed for 
Plasmodium knowlesi, 48 hours for Pf, Pv and Po and 72 hours for Pm [74-76].   
Female mosquitoes, during they blood meal, take up the mature gametocytes. 
In mosquitoes’ midgut, a gametogenesis is initiated with the rapid transformation of 
mature gametocytes into male and female micro and macro gametes, respectively.  
One female gametocyte transforms into one macrogamete, while each male 
gametocyte undergoes three rounds of endomitotic replication to release eight haploid 
and motile microgametes after exflagellation [77, 78]. Fertilisation of macrogametes 
by microgametes results in the formation of diploid zygotes [77], which undergo 
endomeiotic replication to produce a single tetraploid zygote, without nuclear or 
cellular division [77]. Transformation of zygotes results into motile ookinetes, which 
glide over the midgut epithelium apical surface and enter epithelial cells. The 
presence of ookinetes in epithelial cells results in the cell death and extrusion in the 
midgut lumen. During cell extrusion, ookinetes egress and then migrate intercellularly 
to the basal surface of the epithelium [79-81]. Under the basal lamina, ookinetes cease 
movement and continue their differentiation into oocysts [81]. Immediately after 
oocyst formation, several mitotic replications of the four haploid products of the 
meiosis occur within the nucleus with an upregulation of the synthesis of some 
proteins. This results in significant asexual amplification of parasite numbers, termed 
sporogony [82]. Oocyst transformation continues until the formation of sporoblast, 
and is completed with the production of thousands of sporozoites, which bud out of 
the sporoblast. Free sporozoites circulate passively in the haemolymph [83] of the 
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mosquito and then actively invade the salivary glands by gliding motility [84]. In the 
salivary duct, mature sporozoites are ready for inoculation into the vertebrate host 
during subsequent blood-feeding by the infected mosquitoes [85, 86].   
The sexual cycle of malaria parasites in mosquitoes is not a smooth passage. 
Indeed, parasites are exposed to the mosquitoes’ defenses mainly during the ookinete 
stage. It is this stage where the parasite is extracellular and motile in the midgut. The 
mosquito immune system utilizes innate barriers and effectors, but lacks adaptive 
immunity. The main physical barriers are the peritrophic matrix, the midgut 
epithelium and the basal membrane. These barriers provide the first lines of the 
defense against parasites [87] in the invertebrate host. Mosquitoes’ humoral and 
cellular immune responses also contribute significantly to defence against parasite 
infection [88]. Hemocytes are the major immune cells involved in mosquito innate 
immune response [88] and both hemocytes and fat bodies are involved in the release 
of immune effectors implicated in phagocytosis, melanization, nodule formation, 
agglutination, encapsulation and secretion of antimicrobial peptides (AMPs) [89, 90]. 
Hemocytes and other cells are implicated in nitric oxide and reactive oxygen species 
production, which are toxic for malaria parasites [91]. In the humoral immune 
response, mosquitoes’ resistance to malaria parasites, specifically to Pf, has been 
attributed to Anopheles Plasmodium-responsive leucine-rich repeat 1 (APL1) in 
Anopheles gambiae [92]. Each of these humoral and cellular components are 
connected by signaling pathways. These pathways include immune deficiency (Imd), 
Toll, Janus kinase (JNK), and signal transducers and activators of transcription 
(STAT). Toll and Imd pathways are activated when they recognize pathogen-
associated molecular patterns (PAMPs). This activation is important for the nuclear 
translocation of the NF-κB transcription factors Rel1 and Rel2, respectively, which 
activate transcription of immune effector genes such as AMPs and other factors. The 
main classes of AMPs are defensins, cecropins, attacin, and gambicin [89, 93].    
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Figure 1: Malaria life cycle (Blasco et al. 2017) [94] 
 
1.4 Malaria control strategies 
In terms of malaria disease control strategies, WHO recommends the 
following: 
• Management using rapid diagnostic test (RDT) or microscopy for 
confirmation of infection; 
• Treatment with ACT, 
• intermittent preventive treatment for pregnant women (IPTp) and infants 
(IPTi),  
• Seasonal malaria chemoprevention (SMC) for children aged 3 – 59 months in 
the sub-Sahel region of Africa with highly seasonal malaria i.e. Chad, the 
Gambia, Guinea, Mali, Niger and Senegal; and  
• Use of insecticides to control vector populations including insecticide-treated 
mosquito nets (ITN), indoor residual spraying (IRS) and larval control [8]. 
It should be noted that with the exception of larval control, the majority of these 
intervention and management strategies have been implemented in Mali. 
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One of the ways to avoid malaria progression to life-threatening complications 
is early diagnosis as well as effective treatment. As a result of global resistance of Pf 
to antimalarial monotherapies (chloroquine, amodiaquine and sulfadoxine-
pyrimethamine), WHO has recommended the use of ACT for the treatment of 
uncomplicated Pf malaria since 2001 [95]. The recommended ACTs are: AL, ASAQ, 
artesunate-mefloquine (ASMQ), DHA-PPQ, PA, and artesunate-sulfadoxine-
pyrimethamine (ASSP)[39, 96, 97].  
By the end of 2009, ACTs were adopted as national policy for first line 
treatment of uncomplicated Pf malaria in most of the malaria endemic countries [98].  
In Mali, where Pf malaria is responsible for 42% of hospital admissions, the national 
malaria control program (NMCP) has recommended the use of AL or ASAQ for the 
treatment of uncomplicated cases of malaria since 2006 [8]. 
WHO advises monitoring the efficacy, safety, and resistance to antimalarial 
drugs using its standard protocols. The first-line antimalarial drug should be changed 
if the proportion of total treatment failures after molecular correction is ≥ 10%, after 
monitoring (in vivo) for therapeutic efficacy [39].  A number of studies have 
evaluated the efficacy and safety of ACTs, particularly in sub-Saharan Africa, and 
report cure rates of more than 90% after molecular correction as recommended by 
WHO [99-103].  Other studies specific to Mali have shown that ASAQ, ASSP, 
ASMQ and AL are safe and efficacious, with corrected cure rates of more than 95% 
after 28 days of follow-up [102, 104-107].  
While these ACTs are still efficacious in sub-Saharan Africa, there is concern 
about documented parasite resistance to antimalarial drugs, mainly to artemisinin and 
its derivatives, in Southeast Asia [108-110]. Resistance to the partner drugs of 
artemisinin and derivatives have also been reported in Southeast Asia [111-113]. 
Despite maintenance of good efficacy of ACTs in Africa, one study showed a 
declining response of Pf to DHA-PPQ, and to AL in Kenya [114] and other studies 
have identified a persistence of sub-microscopic Pf parasitaemia until day 14 after AL 
treatment [115, 116]. These two studies did not show a clear relation between these 
phenomena and resistance to ACT. However, they emphasise the need for continued 
surveillance of ACT efficacy as recommended by WHO to rapidly detect the 
emergence of parasite resistance in case it does appear in Africa. This 
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recommendation mandates the clinical and parasitological assessment of therapeutic 
efficacy which should include [39]: 
• Confirmation of the quality of the antimalarial medicines tested; 
• Molecular genotyping to distinguish between re-infections and recrudescence, 
and to identify genetic markers of drug resistance; 
• Studies of parasite susceptibility to antimalarial drugs in culture; and  
• Measurement of antimalarial drug levels to confirm adequate exposure in the 
case of slow therapeutic response or treatment failure. 
To these existing anti-malarial tools, vaccines would be a perfect addition. For 
the moment, there is no vaccine for prevention, control, elimination and eradication of 
malaria. The parasites causing malaria have a complex biology that complicates the 
research of vaccines. There are many vaccine candidates, the most advanced to date is 
a pre-erythrocytic stage vaccine, a recombinant circumsporozoite protein vaccine, 
RTS,S/AS01. The target of this vaccine is the Pf circumsporozoite protein (CSP) 
present on the surface of the sporozoites and exported in the cytoplasm of 
hepatocytes. CSP is a major surface protein of the sporozoites. CSP was the key target 
of protective immunity induced by irradiated sporozoite vaccines in animal models 
[117]. The first vaccine candidates targeting PfCSP failed to generate significant 
protection [118]. RTS,S/AS01 was created based on experience during the 
development of the genetically engineered hepatitis B vaccine. RTS,S designate the 
presence of the CSP repeat region (R), T-cell epitopes (T) fused to the hepatitis B 
surface antigen (HBsAg) (S) and assembled with unfused copies of HBsAg (S) [119]. 
The efficacy of this candidate vaccine against clinical malaria, over a period of 
14 months after first vaccination, varied from 30.1% in infants in the younger age 
category (6 to 12 weeks of age at the time of first vaccination) [120] to 50.4% in 
children in the older age category (5 to 17 months of age) [121]. In July 2015, RTS,S 
received a positive scientific opinion from European Medicines Agency (EMA), for 
use outside the European Union.  
The only malaria vaccines which have a vaccine efficacy higher than 90% in 
malaria-naïve volunteers, are based on the whole-parasite vaccine approach. The 
potency of this approach was first shown in 1973 with the use of radiation-attenuated 
Pf sporozoites (PfSPZ) inoculated by mosquito bites [122, 123]. To date, substantial 
progress has been made with the development of this approach. Chemoprophylaxis 
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with sporozoites (CPS) is a second approach, where infectious PfSPZ are inoculated 
by mosquito bites to participants who are under chloroquine (CQ) [124, 125] or 
mefloquine [126] chemoprophylaxis. CPS induces potent, long-lasting immunity. 
Another approach is to use genetically attenuated parasites (GAP), using knockouts of 
P52, P36, sap1 or B9 genes [127-130]. Parasites deficient in these genes can develop 
normally from the asexual erythrocyte stage to the sporozoite stage; however, their 
development is arrested after hepatocyte invasion. The most advanced GAP in clinical 
development is the double-mutant parasite PFSPZ-GA1 produced by the 
biotechnology company, Sanaria, where attenuation is achieved by deletion in b9 and 
sap1 genes, which are indispensable for successful liver-stage development of the 
parasite [130]. In the PfSPZ-chemoprophylaxis vaccine (PfSPZ-CVac): non-
irradiated, aseptic, purified, cryopreserved PfSPZ (PfSPZ challenge) are inoculated 
intravenously in healthy volunteers under CQ chemoprophylaxis. This approach 
protected 100% of malaria-naïve volunteers against controlled human malaria 
infection using the vaccine strain (NF54) [131].     
Proprietary methods have been developed to manufacture, purify, 
cryopreserve and intravenously inject aseptic whole PfSPZ, minimizing the use of the 
complex model of mosquito bites.  
The whole parasite vaccine model is also efficacious in malaria-exposed 
adults, albeit with a substantially reduced degree of protection [132]. A study of the 
safety and efficacy of the PfSPZ vaccine in Mali showed a vaccine efficacy of around 
48% against first infection and 29% against all infections for 6 months during the 
malaria transmission season [132]. Thus, the key goal for malaria vaccine 
development, the generation of robust and long-lasting protection against 
heterologous natural challenge, remains elusive. 
 
1.5 Chemotherapy of malaria 
Anti-malarial drugs constitute one of the critical elements in malaria control 
and prevention. Drugs used for chemotherapy or chemoprevention can be classified 
according to their chemical structure, their use for treatment or chemoprophylaxis, or 
stage-specificity of action. For stage-specificity of action, the recommended 
antimalarial drugs can be sub-grouped into three categories. The majority of anti-
malarial drugs available on the market are drugs with activity against the asexual 
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blood stages only, e.g., CQ, amodiaquine, mefloquine, artemisinins and its 
derivatives, quinine and quinidine, lumefantrine, piperaquine and pyronaridine. These 
drugs are used to treat, or prevent, symptomatic malaria.  
A second group of drugs targets both liver stages and asexual erythrocytic 
forms of Pf, and is comprised of atovaquone, proguanil, pyrimethamine, sulfadoxine 
and all antibiotics with antimalarial action, e.g., azithromycin, doxycyclin and 
clindamycin. 
Primaquine and tafenoquine are representatives of a third group of drugs, with 
activity against liver stages (even latent liver stages) and gametocytes.  
 
1.5.1 Amodiaquine 
AQ is a 4-aminoquinolone compound with schizonticidal activity. Like other 
quinolone-containing drugs, AQ accumulates in the acid-food vacuoles of the 
intraerythrocytic-stage malaria parasite [133, 134]. Pf, during its asexual reproduction 
phase, digests host cell haemoglobin and releases heme, which is toxic for the parasite 
[135, 136]. To detoxify the heme, the parasite polymerizes it to hemozoin. It is 
hypothesised that AQ and related malaria schizontocides act by inhibiting the heme 
polymerase enzyme activity [137].  
WHO recommends the use of AQ in combination therapy with an artemisinin 
derivative. AQ is combined with artesunate in the treatment of uncomplicated Pf 
malaria. The fixed-dose combination of ASAQ was the first treatment made available 
by Drugs for Neglected Diseases initiative (DNDi) in 2007 through a partnership with 
Sanofi and has been included on the WHO Essential Medicines List in 2011. DNDi 
estimated the distribution of 320 million treatments of ASAQ in Africa by the end of 
August 2014 [138].  
AQ is administered at a dose of 10 mg per kg body weight once a day for a 
period of three days. In combination with artesunate, the body weight-adjusted dose 
of AQ ranges between 7.5 – 15 mg per kg per dose [139].  
Since 1990, AQ is no longer advised for prophylaxis due to cases of 
agranulocytosis which were observed in some patients who took the drug for malaria 
prevention [140]. As a result of this toxicity issue, the use of AQ plummeted over the 
late 1980s until 2000s, however, emerging resistance to CQ and sulfadoxine-
pyrimethamine has renewed the interest in AQ as a partner drug for ACT.       
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AQ, with its short terminal half-life of around 5 hours, is metabolised rapidly 
to its main metabolite N-desethylamodiaquine (DEAQ) (Figure 2) [141]. Even at a 
therapeutic dose, AQ concentration is low in plasma, and it is not detectable 8 h after 
administration. AQ and DEAQ exhibit first order pharmacokinetics, meaning that the 
amount of drugs excreted in the urine in a set amount of time is in a linear relationship 
with the amount of drug in the body [142]. DEAQ is an active metabolite of AQ with 
a long half-life of 1 to 3 weeks [143, 144]. AQ and DEAQ bind to plasma proteins 
with a proportion of over 90%. 
AQ is metabolised to DEAQ in the liver mainly by CYP2C8 [145]. This 
cytochrome (CYP) is highly polymorphic, with the variant CYP2C8*2 being the most 
frequent among the mutant forms in the African population. CYP2C8*2 showed slow 
metabolism of AQ (threefold higher Km and six-fold lower intrinsic clearance) [146]. 
The activity of CYP2C8 is not known to be influenced by age or gender [147]. 
AQ toxicity, mainly its role in neutropenia, may be due to its metabolite 
quinoneimine [148]. AQ and DEAQ are also metabolised by extrahepatic CYP 
(CYP1A1 and CYP1B1) to an intermediate metabolite called M2 [145, 149]. This 
intermediate is responsible for the generation of toxic quinoneimine by the action of 
CYP1A1, CYP1B1 (found in peripheral blood leucocytes [151]) and 
myeloperoxidases [150].  
    
1.5.2 Pyronaridine 
Pyronaridine is a schizonticide antimalarial drug, first synthesised in 1970 in 
China, where it has been used alone in the treatment of uncomplicated Pf malaria for 
more than 30 years [152]. The structure of pyronaridine is related to 
4-aminoquinolines, but it is more active than CQ. It is highly active in vitro and in 
vivo on Pf multidrug-resistant parasites, particularly CQ resistant parasites [153-156]. 
The mechanism of action of pyronaridine is explained by its capacity to inhibit 
the formation of β-hematin [157]. It forms a complex with hematin, to enhance 
hematin-induced red blood cell lysis. It also acts in inhibiting glutathione-dependant 
hematin degradation [157-159]  
Pyronaridine is used in a fixed-dose combination with artesunate in a ratio of 
3:1 in the treatment of uncomplicated Pf malaria. The combination PA is available in 
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two formulations: PA granules (60:20 mg) for children and infants between 5 and 
20 kg, and tablets (180:60 mg) for patients weighing more than 20 kg.   
Few methods have been developed to quantify pyronaridine concentrations in 
human whole blood or plasma [160-163]. Pyronaridine concentrations in blood cells 
in rabbits demonstrate blood:plasma ratios which vary from 4.9 to 17.8 [161]. 
Another study in rabbits found blood:plasma ratios ranging from 3 to 6 after 
intramuscular dosing [164]. The blood:plasma distribution of pyronaridine was also 
evaluated in vitro using whole blood in rabbit (2.5 to 3.8) and in human (1.2 to 1.7) 
[152, 165]. Between 92-96% of pyronaridine is bound to plasma proteins [165]. 
After 3-day treatment of malaria patients with a 12 mg/kg daily dose of 
pyronaridine, the estimated time to reach the maximum plasma concentration was 
80.0 ± 79.9 hours, with an elimination half-life of 194.8 hours [166, 167]. 
Cytochrome P450 enzymes, mainly CYP1A2, CYP2D6 and CYP3A4, 
metabolise pyronaridine [165]. Morris CA and al. in 2015 identified nine primary and 
four secondary metabolites of pyronaridine [168]. The routes of excretion of 
pyronaridine and its metabolites are urinary and fecal [168].  
 
1.5.3 Piperaquine 
Piperaquine is a bis-4-aminoquinoline antimalarial drug, synthesised 
independently in 1966 in China and in France [169]. It has been evaluated in China 
for prophylaxis and treatment of uncomplicated malaria [170]. It also has been 
assessed in Africa [171]. The development and use of piperaquine was pursued in 
China until the 1980s. Piperaquine received renewed consideration during the last two 
decades because of Pf resistance to CQ, and due to its long half-life.  
Piperaquine is available in combination with dihydroartemisinin in two 
different strength tablets: 160:20 mg for patients weighing less than 13 kg and 
320:40 mg for patients weighing at least 13 kg. It is administered orally once daily for 
3 days to treat uncomplicated Pf malaria. Following administration to malaria 
patients, the maximum plasma concentration of piperaquine is observed at around 
4 hours, with a median terminal elimination half-life of 23 days. The median day 7 
capillary plasma concentration is around 64 ng/ml with high inter-individual variation 
[172, 173]. Piperaquine is probably metabolised by CYP3A4 [174]. 
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Various methods of detection have been developed to quantify piperaquine in 
different biological matrices such as venous whole blood, plasma, serum, urine and 
capillary whole blood, including the use of HPLC with UV detection or tandem mass 
spectrometric detection [175-179]. Extra care is required during piperaquine 
quantification because it is heavily adsorbed on glass surfaces. To avoid this issue, 
plastic material or silanized glassware has to be used during analytical methods 
development and its quantification [180]. 
The plasma protein binding fraction of piperaquine is estimated to be 97% 
[175].  
 
1.5.4 Lumefantrine 
Lumefantrine, or benflumetol, is an arylaminoalcohol antimalarial drug used 
exclusively in combination with artemether for the treatment of malaria. AL is 
indicated for the treatment of uncomplicated malaria in patients of 5 kg bodyweight 
and above. A 3-day treatment schedule with a total of 6 doses (after the initial dose 
subsequent doses are scheduled at 8; 24; 36; 48 and 60 hours) is recommended 
according to body weight as below:  
     5 kg to less than 15 kg: One tablet per dose (total course of 6 tablets).  
  15 kg to less than 25 kg: Two tablets per dose (total course of 12 tablets). 
  25 kg to less than 35 kg: Three tablets per dose (total course of 18 tablets).  
  35 kg body weight and above: Four tablets per dose (total course of 24 
tablets). 
Lumefantrine has a relatively long half-life (3 – 6 days) and is metabolised to 
desbutyl-lumefantrine. Both lumefantrine and it’s metabolite are active and the 
proportion of desbutyl-lumefantrine found in the body is only 10% of lumefantrine.  
Lumefantrine is a schizonticidal drug. Its mechanism of action is not well 
understood, but some studies show that it binds to hemin to inhibit the formation of ß-
hematin [181]. More than 99% of lumefantrine was found to be plasma protein bound 
[182].    
Lumefantrine is metabolised by CYP3A4, and it inhibits CYP2D6 [183]. 
CYP3A4 is the most abundant CYP expressed and accounts for approximately 30 to 
40% of the total CYP content in human adult liver and small intestine. CYP3A4 
activity is higher during infancy (around 120%) than that of adults. Its activity and 
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expression are also higher in women than in men [184, 185], which can have an 
impact on the pharmacokinetic profile of its substrates like lumefantrine.  
Analytical methods have been developed to quantify lumefantrine and its 
metabolite in plasma; and in whole blood spotted onto filter paper using HPLC with 
UV detection or tandem mass spectrometric detection [186, 187]. Precaution has to be 
taken to avoid evaporation of the processed eluates containing lumefantrine in plastic 
tubes. Lumefantrine can be adsorbed on plastic surfaces [186]. Whole blood spotted 
onto filter paper is a simple method for sample collection and storage prior to the 
quantification of antimalarial drugs. Lumefantrine extraction recovery from filter 
paper is weak. To salvage extraction recovery, pre-treatment with 0.75 M tartaric acid 
and storage at 4ºC is required [188]. Another method is based on the use of 1.6 mol/L 
phosphoric acid for pre-treating sampling paper [189].   
 
1.5.5 Artemisinin (Qinghaosu) 
Artemisinin, isolated from Artemisia annua is a sesquiterpene lactone with an 
endoperoxide bridge. Artemisinin and its derivatives are the most potent antimalarial 
drugs currently in use [63]. Their use as mono-therapy is not advised; however, use of 
artemisinin and its derivatives in combination with other antimalarial drugs with 
different mechanisms of action is the recommended first-line treatment in all malaria 
endemic countries. Artemisinin activation is heme-dependent [190]. It acts by binding 
to many proteins which are implicated in essential biological processes of the parasite 
[190]  
 
1.5.6 Artemether 
Artemether is a semi-synthetic derivative of artemisinin used in the treatment 
of Plasmodium spp. It is administered in combination with lumefantrine to treat 
uncomplicated malaria caused by Pf or any case of uncomplicated malaria due to 
other Plasmodium species. Artemether, with its short half-life, has a high parasite 
reduction ratio (PRR), which leads to a rapid symptomatic relief. The function of 
lumefantrine in this combination is to eliminate the remaining parasites.  
Artemether is metabolised by cytochrome P450 3A4 and 3A5 to the active 
metabolite dihydroartemisinin (Figure 2). Artemether and its active metabolite have 
short half-lives of 2 – 4 hours and 1 -2 hours respectively. 
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Artemether and its metabolite are endoperoxide antimalarial drugs, which like 
other endoperoxide antimalarials, are activated by heme or ferrous ions to generate a 
cytotoxic radical species (oxygen and carbon-centered radicals).  
Artemether and its metabolite bind to plasma protein with different degrees, 
92 to 98% for artemether and 47 to 76% for dihydroartemisinin [191]. 
Methods have been developed to quantify artemether and its active metabolite 
in human plasma by high-performance liquid chromatography after derivatization or 
by liquid chromatography-tandem mass spectrometry with electrospray ionisation and 
atmospheric pressure chemical ionisation [160, 192-194]. To date, there is no method 
to quantify artemisinin and its derivative from samples collected onto filter paper.  
 
1.5.7 Artesunate  
Artesunate is also a semi-synthetic derivative of artemisinin used in 
combination for the treatment of malaria. Because of its solubility in water, artesunate 
is used for parenteral administration in the treatment of severe malaria. 
For the treatment of uncomplicated malaria, particularly Pf malaria, artesunate 
is combined with AQ or pyronaridine.  
Artesunate has a short half-life of less than one hour. CYP2A6 metabolises it 
to the active metabolite dihydroartemisinin, which is further metabolised by 
glucuronosylation to an inactive metabolite. Its mechanism of activation and mode of 
action mirror those of artemisinin and its other derivatives. 
Methods have been developed to quantify artesunate and its active metabolite 
in plasma. 
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Figure 2: Metabolism of the Anti-Malarial Agents Lumefantrine, Amodiaquine, 
Artesunate and Artemether 
 
1.5.8 Preclinical antimalarial drug candidates with multiple-stage activity 
Most of the antimalarial drugs in preclinical development are derived from 
screening of many thousands of compounds, using diversity-oriented synthesis with 
high-throughput phenotype-based screens.  
For malaria control, elimination and eradication, new antimalarial drugs need 
to meet requirements such as a mechanism of action different from the currently 
used antimalarial drugs, they must cure liver stages, cure the asymptomatic blood 
infections, prevent transmission by killing or preventing development of sexual 
stages, be suitable for mass administration, and ideally achieve this with single dose 
administration[195]. Current preclinical antimalarial drug candidates which meet 
these requirements include DDD107498, bicyclic azetidine series, and NITD609. 
DDD107498 is a new multiple-stage activity antimalarial agent that inhibits 
protein synthesis. Beatriz Baragana and colleagues discovered DDD107498 after 
screening 4,731 compounds. DDD107498 is derived from a 2,6-disubstituted 
quinoline-4-carboxamide scaffold and contains a fluorine atom, an ethyl-pyrrolidine 
group, and a morpholine group. DDD107498 has demonstrated activity against liver 
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stage parasites, blood stage parasites, and both male and female gametocytes. 
Baragana and colleagues identified translation elongation factor 2 (eEF2) as the 
molecular target of DDD107498. This factor is essential for protein synthesis [196].   
Bicyclic azetidine series: These series are also novel multiple-stage 
antimalarial inhibitors, discovered after screening 100,000 compounds using a 
phenotypic blood-stage growth inhibition assay. The resulting compound, BRD3444, 
was modified to improve its physicochemical and pharmacokinetic properties, with 
the synthesis of BRD1095 and BRD7929 by replacement of hydroxymethyl at 
position C2 with aminomethyl and dimethyl aminomethyl substituents. These 
compounds are active against all parasite life stages, after a single oral exposure, and 
they act by inhibition of Pf cytosolic phenylalanyl-tRNA synthetase [197]. 
NITD609 is a potent antimalarial drug active against Pf and Pv blood stages 
at a low nanomolar concentration [198]. It can be orally administered once daily. 
NITD609 (spirotetrahydro-β-carboline or spiroindolone) was discovered after 
screening 12,000 both pure natural products and synthetic compounds [198]. 
NITD609 acts by rapid inhibition of protein synthesis in Pf [198]. Point mutations in 
the gene of P-type cation-transporter ATPase4 (PfATP4) are responsible for parasite 
resistance to this drug [198].  
 
1.5.9 Pharmacokinetic characteristics of antimalarial drugs 
The pharmacokinetic characteristics of antimalarial drugs are evaluated by 
using a classic pharmacokinetic study. The area under the curve (AUC) is the best 
pharmacokinetic parameter for the determination of treatment outcome in 
uncomplicated malaria [63, 199]. However, the determination of AUC necessitates 
collection of samples at multiple time points from the same patient, making it time-
consuming, painful for small children, work-intensive due to the requirement for large 
numbers of samples for processing and analysis. Studies have found a good 
correlation between the day 7 concentration of lumefantrine, sulfadoxine and 
pyrimethamine and the AUC of these drugs [200]. This observation implies that  
sample collection at one time point (day 7) may be used as a surrogate measure of 
total exposure [201].   
To date, the day 7 concentration of long half-life antimalarial drugs is 
increasingly used as a surrogate of AUC and a predictor of treatment failure [191, 
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202-205].  Validating the use of day 7 plasma concentrations of lumefantrine and 
other partner drugs of artemisinin and its derivatives as a good parameter for the 
determination of treatment outcome in uncomplicated malaria, is needed for repeat 
treatment episodes.   
Blood drug concentration does matter when treating patients. A blood drug 
concentration that is too low can lead to treatment failure and/or induction of parasite 
resistance, whereas excessive blood drug concentrations may be toxic. Achieving the 
appropriate drug concentration in circulating blood is multifactorial. This can be 
linked to both genetic and non-genetic factors. Genetic factors include the human 
enzymes implicated in drug absorption, metabolism and elimination. Non-genetic 
factors include age [206], sex, disease status [207], ethnicity, food intake [206], and 
concomitant treatment [208]. Because of these factors, there is high inter-individual 
variability in the pharmacokinetic profile of antimalarial drugs leading to treatment 
failures and drug-related adverse events in patients. 
 
1.5.10 Analytical methods for antimalarial drugs quantification 
High-performance liquid chromatography methods and mass spectrometry 
methods have been developed to quantify lumefantrine, AQ and DEAQ in plasma and 
whole blood [160, 188, 209, 210]. Fewer methods have been developed for the 
quantification of pyronaridine [160, 161].      
Mass spectrometry is more specific and sensitive than HPLC, its drawback is 
that the instruments are expensive and the cost of analysis per sample is more than 4 
times the costs compared to HPLC. This kind of device is not affordable in most of 
the malaria endemic countries in sub-Saharan Africa.  
Whole blood spotted onto filter paper for quantification of drugs is a simple 
technique and requires less blood volume compared to plasma or serum. For 
quantification of lumefantrine, pre-treatment of filter paper is required to achieve 
acceptable extraction recovery. To date, there is no filter paper method validated for 
quantification of pyronaridine. 
The majority of analytical techniques used for the quantification of 
antimalarial drugs in biological fluids are HPLC and mass spectrometry, particularly 
liquid chromatography coupled with tandem mass spectrometry. 
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These techniques can be divided into two parts, sample extraction, and 
measurement of the given analyte (separation stage and detection stage) [211]. 
 
1.5.10.1 Sample extraction  
Sample extraction consists of separating the analyte from the other 
constituents of the matrix. Many techniques are used for this purpose, including 
protein precipitation, liquid-liquid extraction, and solid phase extraction. 
Liquid-liquid extraction consists of extracting the analyte by using two 
different immiscible liquids, generally one aqueous phase and one organic solvent 
phase. The analyte is partitioned between the two phases according to its solubility.   
This technique is widely used to extract a broad range of analytes, and it has a 
good extraction recovery. Like protein precipitation, it is a non-specific method. 
Hydrophobic constituents of the biological fluids can contaminate the final extract. 
Compared to the two other techniques, it is time-consuming and generates a lot of 
organic solvent waste. 
 
1.5.10.2 Measurement 
In biological fluids, this step is divided into separation of mixtures and 
detection.  
Separation 
The most commonly used laboratory technique for the separation of mixtures 
containing antimalarial drugs is liquid chromatography, mainly HPLC. The technique 
is based on the differential partitioning of the components of the mixtures between the 
stationary and mobile phase. In HPLC, the stationary phase is embedded inside a tube 
(column). Inside the column, the mixtures pass through the stationary phase driven by 
the mobile phase at high pressure. Depending on the polarity of the stationary and 
mobile phase there is a normal-phase liquid chromatography and reversed-phase 
liquid chromatography. 
In reversed-phase liquid chromatography the stationary phase is non-polar 
while the mobile phase is polar. The silica particles of the stationary phase are 
modified by the addition of straight-chain alkyl group having 8 or 18 carbon atoms. 
The non-polar molecules (analytes) are retained while the polar one passes through 
more quickly on the stationary phase. The non-polar molecules are retained because 
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of their hydrophobic interactions with the non-polar stationary phase. The more the 
contact surface area between the non-polar segments of an analyte and the stationary 
phase is high, the more the analyte is retained. The solution mixtures, driven by the 
mobile phase under high pressure, are separated on the stationary phase of the column 
according to their polarity. 
Reversed-phase HPLC is easier to use than a normal-phase, it is robust and 
can be applied to a wide range of analytes especially organic analytes. 
Reversed-phase HPLC methods have been developed to quantify the majority 
of antimalarial drugs. 
Besides normal and reversed-phase HPLC, methods of separation include ion-
exchange chromatography, size-exclusion chromatography, affinity chromatography, 
chiral chromatography and supercritical fluid chromatography. 
 
Detection 
The most commonly used detectors for the identification of antimalarial drugs 
are ultraviolet (UV), mass spectrometry (MS), fluorescence, and electrochemical 
detection. 
Ultraviolet detection technique is the frequently used detection method for 
quantification of antimalarial drugs by HPLC. Analytes are detected because they 
absorb light in the UV wavelength range (100nm to 400 nm). The most commonly 
used solvent in HPLC-UV mobile phase is water, which absorbs UV light at 190 nm. 
Thus, to avoid false reading, UV wavelengths higher than 210 – 220 are used for 
detection. For HPLC-UV detection, in addition to water, UV transparent solvents are 
used as a mobile phase.  
In the range of these UV wavelengths, analytes absorb the light because of the 
presence of the functional groups (chromophores), which absorbs UV light. The 
absorbance (A) of an analyte is proportional to its concentration (C) and the path 
length (l) of the solution as stipulated in Beer-Lambert law. 
 
                                              A = εlC     
Where ε is absorption coefficient of the analyte. 
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UV detection is the cheapest form of detection; it is robust, easy to manipulate 
and sensitive. The disadvantage of this type of detection with antimalarial drugs is its 
inability to quantify artemisinin and its derivatives because these drugs do not have a 
chromophore group to absorb UV light. The other disadvantage is that it is not 
sensitive enough to quantify long half-life antimalarial drugs at their terminal 
elimination phase. 
Accurate, precise, and reproducible HPLC-UV methods have been developed 
to quantify antimalarial drugs from samples collected from malaria patients. 
UV detectors, with variable wavelength, are preferred compared to a fixed 
wavelength. Variable wavelengths are more sensitive because they quantify analytes 
at peak absorption wavelength. Variable wavelength detectors include a diode array 
detector (DAD or PDA), which can scan a wide range of wavelengths simultaneously 
and quantify the analyte at its maximum absorption wavelength. Diode array 
detection can also be used to identify unknown metabolites and to verify the purity for 
an analyte. 
For quantification of artemisinin and its derivatives, and to resolve the 
problem of sensitivity during quantification of antimalarial drugs at their terminal 
elimination phase many laboratories use MS detection. 
 
1.6 Evaluation of drug efficacy 
Control and elimination of malaria requires the use of effective antimalarial 
drugs. WHO recommends bi-yearly monitoring of the first- and second-line 
antimalarial drugs adopted by the national malaria control programmes. These 
medicines have to be changed if their molecular corrected cure rate falls below a 
threshold of 90% [39]. To better evaluate the efficacy of adopted and new 
antimalarial drugs, and to allow comparability between trials, WHO recommends 
standardized protocols to determine PCR-corrected adequate clinical and 
parasitological response cure rates [212, 213]. Besides these in-vivo standard 
protocols, there are ex-vivo, and in-vitro methods to guide the evaluation of drug 
sensitivity. 
For an in-vivo test (Figure 3), patients that receive treatment are followed 
during 28 or 42 days according to the elimination half-life of the drug, to assess 
clinical and parasitological outcomes of the treatment [214-216]. During these follow-
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up periods clinical and parasitological parameters are collected at different time 
points. Responses to treatment are classified as follows for all levels of malaria 
transmission according to WHO [213]: 
- Early treatment failure (ETF) 
o Danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitaemia; 
o Parasitaemia on day 2 higher than day 0, irrespective of axillary temperature; 
o Parasitaemia on day 3 with axillary temperature ≥ 37.5 ˚C; and 
o Parasitaemia on day 3 ≥ 25% of count on day 0.     
- Late clinical failure (LCF) 
o Danger signs or severe malaria in the presence of parasitaemia on any day 
between day 4 and day 28 (day 42) in patients who did not previously meet any 
of the criteria of early treatment failure; and    
o Presence of parasitaemia on any day between day 4 and day 28 (day 42) with 
axillary temperature ≥ 37.5 °C in patients who did not previously meet any of 
the criteria of early treatment failure. 
- Late parasitological failure (LPF) 
o Presence of parasitaemia on any day between day 7 and day 28 (day 42) with 
axillary temperature < 37.5 °C in patients who did not previously meet any of 
the criteria of early treatment failure or late clinical failure. 
- Adequate clinical and parasitological response (ACPR) 
o Absence of parasitaemia on day 28 (day 42), irrespective of axillary 
temperature, in patients who did not previously meet any of the criteria of early 
treatment failure, late clinical failure or late parasitological failure. 
With artemisinin and its derivatives and ACTs, parasite clearance half-life is 
used for identification and surveillance of resistance to artemisinin derivatives. 
Delayed or slow parasite clearance time defined by an elevated parasite clearance 
half-life is considered to be an indicator of resistance to artemisinin and its derivatives 
[217].  
In-vitro and ex-vivo methods monitor the sensitivity of parasites to 
antimalarial drugs.  These methods are not affected by human immunity. In an ex-vivo 
test, parasites collected from malaria patients are exposed to increasing drug 
concentrations to evaluate their susceptibility. In an in-vitro test, parasites are adapted 
in the laboratory before evaluating their sensitivity to a drug. Many ex-vivo and in-
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vitro assays have been established for screening and evaluating the sensitivity of 
antimalarial drugs. There are methods based on schizont maturation [218, 219], 
radioisotope assays [220-223], immunoassays [224-227], high throughput screening 
[228], and fluorescence-based assays [222, 229]. The ring-stage survival assay (RSA) 
[230] is considered to be the best method for evaluating the sensitivity of parasite 
isolates or clones to artemisinin and derivatives in-vitro and ex-vivo.  
All in-vitro tests except the macrotechnique of Rieckmann et al. [218] are 
based on the in-vitro method for continuous cultivation of Pf of Trager and Jensen 
[231].  In addition to in-vivo, ex-vivo and in-vitro assays, molecular methods have 
also been developed for the surveillance of Pf resistance to antimalarials drugs. 
Mutation in Pf CQ resistance transporter gene is a marker of resistance to CQ [232] 
and can be used as a molecular tool for surveillance of CQ resistance in-vivo [233]. 
Dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) quintuple 
mutations predict resistance to sulfadoxine-pyrimethamine in-vivo [234, 235]. The 
presence of two mutations (DHFR Arg-59, and DHPS Glu-540) also predicts 
sulfadoxine-pyrimethamine failure [235]. 
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Figure 3: In vivo model of parasite and drugs interaction.  
(black line) Infection with high parasitaemia which declines after treatment and becomes 
undetectable at day 2 - these parasites may be completely cleared if they are sensitive or they 
may recrudesce if they are resistant to the drugs.  
(black dot line) Recrudescent infection with undetectable parasitaemia from day 2 to day 25 -
parasitaemia becomes apparent after day 25.  
(green line) New infection unrelated to the first one can appear and become detectable when 
the drug concentration falls below the inhibitory concentration.  
(blue line) Concentration profile of the drugs administered once a day during three days. 
 
1.7 Antimalarial drug resistance  
Resistance to a drug is defined as “the ability of a parasite strain to survive 
and/or multiply despite the administration and absorption of medicine given in doses 
equal to or higher than those usually recommended” [38]. Resistance has been 
described to almost all of the classes of antimalarial drugs. Resistance can be due to 
mutations and/or amplification of specific genes encoding drug targets, transporters, 
or proteins involved in maintaining cellular homeostasis.  
The first antimalarial drug to which resistance was documented worldwide 
was CQ. Resistance to CQ was first described in 1957 in Southeast Asia, particularly 
in Thai-Cambodian border. At least six origins of Pf CQ-resistant parasites have been 
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documented [236]. CQ resistance spread to reach Africa in 1978 [237], reaching Mali 
in 1987 [238]. 
In 1967, SP replaced CQ as the first-line treatment of uncomplicated malaria 
in Thailand. Cases of resistance to those drugs have since been documented in 
Thailand [239, 240]. SP resistance spread from Thailand to the other South-East 
Asian countries. Resistance to SP arose and became widespread in the late 1990s in 
Africa [241, 242]. 
Atovaquone was introduced in 1996, and resistance was described in the same 
year [94]. Bark extracts, which contains quinine were used since 1632 for the 
treatment of malaria. The first case of resistance to quinine was described in 1910 
[94]. For mefloquine, the first case of resistance was described in 1982 after its 
introduction in 1977 [94].  
Mutations in the gene coding for a protein termed Plasmodium falciparum CQ 
resistance transporter (PfCRT) are responsible for the resistance of Pf to CQ. A single 
point mutation, resulting in the substitution of lysine by threonine at amino acid 
position 76 of the PfCRT is the key mutation that confers resistance [232, 243]. The 
gene, which codes for the protein PfCRT, is located on chromosome 7. PfCRT is a 
424 amino acid transmembrane protein in the digestive vacuole of malaria parasites. 
Other mutations in PfCRT, which confer resistance to CQ in association with K76T 
are C72S, M74I, N75E, A220S, Q271E, N326S, I356T, and R371I [243]. 
These PfCRT mutations have also been implicated in resistance to quinine, 
AQ and piperaquine [244-247]. However, the presence of PfCRT K76T mutation 
enhances the susceptibility of Pf to lumefantrine [246]. 
Many studies showed the role of Pf multidrug resistance protein 1 in 
antimalarial drug resistance. The gene (Pfmdr1), which codes for the protein with the 
same name, is located on chromosome 5. PfMDR1 is a transmembrane protein 
located in the digestive vacuole of the parasite. It belongs to the ATP-binding cassette 
(ABC) superfamily [248]. Mutations in this gene (N86Y, Y184F, S1034C, N1042D 
and D1246Y) have been implicated in drug susceptibility to CQ, quinine, mefloquine, 
halofantrine, piperaquine, lumefantrine and artemisinins [249, 250]. Lumefantrine, 
mefloquine and dihydroartemisinin are slightly more active against parasites 
harbouring the N86Y mutation, while these parasites are resistant to CQ and DEAQ 
[250]. Copy number variation of Pfmdr1 has been associated with resistance to 
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quinine, mefloquine, lumefantrine, halofantrine and artemisinin [112, 251, 252]. Copy 
number variation of Pfmdr1 is not common in Africa [250]. 
Decreased susceptibility of Pf to quinine is associated with polymorphism of 
Pf sodium hydrogen exchanger (PfNHE1). Pfnhe1 is located on chromosome 13 and 
codes for protein, which is a transmembrane protein of Pf plasma membrane [253]. 
Polymorphism of the microsatellite ms4760 consisting of a DNNND repeat unit in 
Pfnhe1 is associated with decreased susceptibility to quinine [253, 254]. 
Resistance to pyrimethamine and sulfadoxine is associated with mutations in 
Pf dihydrofolate reductase-thymidylate (Pfdhfr) synthase and Pf dihydropteroate 
synthetase (Pfdhps), respectively. Pfdhfr-ts is located on chromosome 5 of Pf and 
codes for the PfDHFR and thymidylate synthase proteins. PfDHFR catalyzes the 
reduction of dihydrofolic acid to tetrahydrofolic acid in the tetrahydrofolate synthesis 
pathway, which is required for the essential synthesis of purines. DHPS is an enzyme, 
which catalyzes the synthesis of dihydropteroate from para-aminobenzoic acid 
(PABA) during folate synthesis. Mutations on Pfdhfr at positions (S108D, N51I, 
C59N, and I164L) and Pfdhps at positions (S436A/F, A437G, L540E, A581G, and 
A613T/S) are associated with sulfadoxine-pyrimethamine resistance [255-258].  
PfDHFR mutations at codon position A16V and S108T are associated with 
cycloguanil resistance [259]. 
Resistance to atovaquone, which acts against the malaria parasite by inhibiting 
the mitochondrial electron transport chain, is associated with point mutations in the 
gene coding for the CYPbc1 protein. The mutation at position Y268N/S/C of CYPbc1 
is associated with atovaquone resistance [260, 261]. 
Treatment responses to artemisinin and derivatives are evaluated by 
determining parasite clearance parameters. Parasites with slow or delayed clearance 
after artemisinin treatment are considered as tolerant. In Southeast Asia, mutations in 
the gene coding the Kelch propeller (K13-propeller) domain were associated with 
delayed parasite clearance after artemisinin treatment [110]. The K13-propeller is a 
protein encoded by a gene situated on chromosome 13, and it has many functions 
[262]. It is implicated in protein-protein interaction [263]. Among K13-propeller 
mutations, C580Y, R539T, and Y493H are the three most commonly associated with 
delayed clearance after treatment of malaria patients with ACTs [110].   
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Drug-resistant parasites have also been reported in Pv. Pv resistance is hard to 
evaluate because of relapses. Dormant liver stage (hypnozoites) can recur as early as 
3 weeks after initial infection depending on environmental conditions [264]. Cases of 
CQ resistance of Pv were reported from Papua New Guinea in 1989 and from 
Indonesia in 1991 [265, 266]. Pv resistance was also reported for mefloquine and 
sulfadoxine-pyrimethamine. 
The study of the molecular mechanisms of Pv resistance is based on 
identifying homologues of key genes implicated in Pf resistance. Pvcrt, the homolog 
of Pfcrt in Pf, is not involved in Pv resistance to CQ. A mutation of Pvmdr1 
conferring a change at codon position Y976F was strongly associated with Pv 
resistance to CQ [267, 268]. Pv resistance to mefloquine, as with Pf resistance, is 
associated with copy number variations of Pvmdr1. Parasites with an amplification of 
Pvmdr1 were less susceptible to mefloquine [269].  
Analogous to Pf, a set of mutations of Pvdhfr and Pvdhps has been reported to 
affect the susceptibility of Pv to pyrimethamine and sulfadoxine, respectively [270-
273]. Four mutations have been reported in Pvdhfr (F57L/I, S58R, T61M, and S117T) 
and three in Pvdhps (S382A, A383G, and A553G).              
 
1.8 Distinction between recrudescence and new infections for monitoring 
the antimalarial drug therapeutic efficacy against Pf  
In malaria endemic countries, WHO recommends the use of molecular 
genotyping in the assessment of therapeutic efficacy of antimalarial drugs against Pf 
to distinguish between recrudescence and reinfections. To differentiate recrudescent 
infections from reinfections, polymorphic genes such as merozoite surface protein 2 
(msp2), merozoite surface protein 1 (msp1), glutamate-rich protein (glurp), and 
microsatellites such as ca1 and ta99 are used. One of the limitations of this technique, 
in a high-endemicity area, however, is the multiplicity of infection at the baseline 
before treatment. Minority parasite population genotypes may not be detected at 
baseline, but if these parasites are resistant to the treatment, they could be detected 
during follow-up and then classified as reinfection [274].  
Merozoite surface protein 2 is a 45-kDa merozoite surface antigen of Pf. It is 
encoded by a single exon on chromosome 2. Structural diversity in this protein allows 
the classification of Pf into two families (FC27 and 3D7). The protein can be divided 
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into five regions including two highly conserved regions (block 1 and 5) flanking two 
semi-conserved regions (block 2 and 4) and a highly variable and repetitive region 
(block 3) [275, 276]. 
The two families have two conserved regions in common: the 43 N-terminal 
residues and the 74 C-terminal residues. In the 74 C-terminal residues, the FC27 
sequence differs from 3D7 sequences by a single nucleotide polymorphism at position 
89 bases from the terminal codon. The consequence of this mutation is the 
substitution of a serine in the MSP2 protein of FC27 by asparagine in 3D7. 
Semi-conserved blocks are characterised by non-repetitive variable regions. 
The variations are specific to each family.  
For variable region (block 3), FC27 isolates contain two identical copies of a 
32-amino acid repeat, starting at base pair number 178. The 3D7 contains multiple 
copies (5 copies) of a 12-bp repeat starting at position 169. The 3D7 isolates contain 
other multiple copies of a 9-bp repeat that code for the amino acid threonine (poly-
threonine region). Figure 4 represents a gene model for msp2 showing FC27 and 3D7 
families.  
Because of these size variations, parasite clones can be differentiated by size 
polymorphism in each family.  
 
Figure 4: Gene model of the msp2.  
Green arrows show the annealing position of primers of the first amplification. Red arrows 
show the annealing position of primers of the second amplification. 5’ and 3’ represent the 
five and three prime end of DNA. (fsp) flanking the semi-conserved part. Black blocks are the 
conserved (cons) part between the two families except one single nucleotide polymorphism 
(SNP) in 3’ cons of FC27. (bp) base pair 
 
MSP1 is a surface protein of the Pf merozoite, anchored in the membrane by a 
glycosylphosphatidylinositol moiety [277]. It is an 185-195 kDa glycoprotein. The 
gene coding for MSP1 is localised on chromosome 9 and is used for the 
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discrimination of parasite clones. This gene can be divided into 17 blocks: 5 
conserved blocks (block 1, 3, 5, 12 and 17), 5 semi-conserved blocks (block 7, 9, 11, 
14 and 15) and 7 highly variable blocks [278, 279].  
Figure 5 depicts the gene model for msp1. 
The variable block 2 is characterised by tripeptide (9 base pairs) repeats in the 
MAD20 and K1 families, while there are no tripeptide repeats in the RO33 family. 
The repeat numbers vary between 5 to 25 for K1 and 5 to 16 for MAD20. In K1 there 
is glutamine and proline rich region in block 8, which is absent in MAD20 and RO33. 
Apart from block 2 repeats, RO33 is similar to MAD20 [279-282].  
      
Figure 5: Gene model of the msp1.  
Arrows show the annealing place of primers of the second amplification 
 
Microsatellite ca1 is a non-coding sequence used for the genetic analysis of 
Pf. It is characterised by the repetition of the simple nucleotide sequences at and atatt 
(Figure 6). These repetitions vary between parasites and can be used for 
discrimination. This microsatellite is located in the intron of the calmodulin gene of 
Pf [283, 284]  
 
           
Figure 6: gene model of the microsatellite ca1.  
Arrows show the annealing place of primers of the second amplification. (at repeat) repetition 
of adenine and thymine. Numbers below at repeat are the number of time of at or atatt. 
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Research question 
The human populations of endemic countries pay a heavy price to malaria, 
mainly in sub-Saharan Africa where incidence of disease remains high. Children can 
suffer more than five malaria episodes per year in areas where the transmission is 
seasonal or perennial [11, 104, 285]. The consequence is more than 5 repetitive 
treatments with an ACT. The efficacy, safety, as well as pharmacokinetic properties 
of these ACTs have mostly been studied for the management of single episodes of 
malaria. The question posed in this thesis is a focus on the relationship between the 
day 7 concentration of lumefantrine, desethylamodiaquine, piperaquine and 
pyronaridine and parasite recurrence, drug-related accumulation and safety following 
repeat treatment for multiple malaria episodes with the same drug (AL or ASAQ or 
DHA-PPQ or PA) during a period of two years of follow-up. 
 
1.9 Hypothesis   
It was hypothesized that day 7 concentrations of lumefantrine, 
desethylamodiaquine, pyronaridine and piperaquine are implicated in parasite 
recurrence and drug-related safety after repeated treatment with the same ACT during 
a period of two years of follow-up.  
1.10 Objectives: 
Main objective: To help to define the risk of parasite recurrence and drug- 
related safety as a function of the pharmacokinetic and pharmacodynamic 
characteristics of the slowly eliminated artemisinin combination partner drugs after 
repetitive treatment with the same ACT during two years. 
 
Specific objectives: 
 
 Determine the genotypes of Pf infections at baseline and at day of 
recurrence after treatment with these ACTs using the polymorphic parasite genes 
msp2, msp1 and the microsatellite ca1. 
 Develop and validate a HPLC method to quantify lumefantrine, 
desethylamodiaquine, pyronaridine and piperaquine in plasma. 
 Determine the day 7 concentration of lumefantrine and DEAQ in the 
study population after repetitive treatment with AL or ASAQ 
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 Determine the threshold of day 7 plasma concentration of ACT partner 
drugs (lumefantrine and desethylamodiaquine) that can identify patients at high risk 
of rapid recurrence 
 Determine the relationship between day 7 concentration of the partner 
drugs (lumefantrine and desethylamodiaquine) and incidence of adverse events  
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2 Methods 
2.1. In vivo methods 
2.1.1. Study sites:  
Samples included in this sub-study were from three sites in Mali (Sotuba, 
Bougoula-Hameau and Kollé). At these three sites, the dominant malaria species is Pf 
occurring with an incidence of more than 95% of malaria cases. 
Sotuba 
Sotuba is a peri-urban area of Bamako capital city of Mali where malaria is 
mesoendemic with seasonal transmission. The entomological inoculation rate (EIR) is 
less than 4 infected bites per person per month during transmission season [286]. The 
peak of malaria transmission is between August and September. The population is 
estimated to be around 5665 inhabitants. It is a mixed population with no dominant 
ethnic group. The study started in Sotuba first in November 2011, where PA was 
compared to AL in adult patients (above 15 years).  
Bougoula Hameau 
Bougoula Hameau is a peri-urban village next to Sikasso, at 375 km southeast 
from Bamako. The population is estimated to be around 5,000 inhabitants. Senoufo is 
the major ethnic group. Malaria is hyper-endemic and seasonal. Bougoula-Hameau 
has a longer and intense transmission season (June to November), with an EIR of 
around 300 infected bites per person per month during the transmission season. The 
peak of transmission is between August and September. 
Kollé 
Kollé is a rural village situated in the southwest at around 57km of Bamako. 
The transmission is hyper-endemic and seasonal (June-October) with an EIR of 
around 100 infected bites per person per month. The peak of malaria transmission is 
between August and September. In Kollé area the population is estimated to 20,000 
people. The major ethnic group is Malinké. 
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Figure 7: Study sites 
 
2.1.2. Study design: 
This sub-study is part of the WANECAM study, a large clinical trial which is 
a comparative, randomised, multicenter, open-label, parallel 3 arm study to assess the 
safety and efficacy of repeated ACT therapy over a period of 2 years in children and 
adults with uncomplicated Plasmodium sp. malaria at enrolment.  At each site, 
eligible participants were randomised to one of 3 treatment arms DHA-PPQ, PA, and 
first line treatment of the ACT (either AL or ASAQ) [287].  
Data from this sub-study was collected from participants in Mali.    
PA, DHA-PPQ and AL were administered at all of the three studies sites 
(Sotuba, Kollé and Bougoula Hameau), while ASAQ was used in Bougoula Hameau 
only (according to the main study plan). 
At all of the three study sites, PA was compared to AL. In Sotuba and Kollé 
DHA-PPQ was compared to AL and in Bougoula Hameau DHA-PPQ was compared 
to ASAQ. During this sub-study, a formal comparison between treatment arms was 
not made.  
Once a patient was randomised to a treatment arm, he/she received the same 
study drug for the subsequent uncomplicated malaria episodes for up to 2 years after 
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the first randomization. Complicated malaria or treatment failure cases (early 
treatment failure or late clinical) occurring before day 28 of follow-up were treated 
with quinine or artesunate, and then for safety reasons, the follow-up was completed 
at day 42 and considered as treatment failure and reported as such. Subsequent 
uncomplicated clinical malaria occurring at least 4 weeks apart received the same 
ACT and followed for ACPR assessment over the two-year study period.  
Symptomatic malaria recurrences between 28 days and day 42 were treated 
with the same initially randomised study drug as an uncomplicated malaria case and 
followed up to day 42 or 63. 
The period of administration for each of the study drugs was three days. At the 
baseline visit, patients that met study eligibility criteria were randomly assigned to 
one of the above treatment arms. Local guides or a health worker performed a 
monthly scheduled home visit, to document the presence and health status of the 
patient, and to monitor the patient's movements from the immediate locality. 
Participants were reminded to come to the study clinic for any health issue. All 
malaria episodes during the study period were treated and followed by the study team. 
All of the treatments were administered under the supervision of the study 
teams. Participants were hospitalised during the treatment period. 
Participants were actively followed during the treatment period, and also 
specifically on day 7, day 14, day 21, day 28, day 35 and day 42 to assess treatment 
efficacy and safety.  
Passive follow-up was continued after the 42 days for safety assessment 
throughout the two-year period of the study. 
Plasma samples were collected at day 7 of follow-up after treatment with 
study drugs for pharmacokinetic study. 
 
2.1.3. Study Population 
The study population consisted of all eligible patients at the study sites with 
microscopically confirmed acute, uncomplicated Plasmodium sp malaria. 
 
2.1.4. Inclusion and non-inclusion criteria: 
Patients had to satisfy the following inclusion criteria to be eligible for the 
study: 
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- Male and female patients aged from 6 months and above  
- Body weight equal or above 5 kg 
- Microscopically positive cases of Pf with parasite density less than 
200,000 parasites per μl, and fever, as defined by axillary temperature 
≥ 37.5°C, or history of fever in the previous 24 hours (not needed at 
reinclusion) 
- Ability to swallow oral medication 
- No documented malaria treatment during the last two weeks 
- Ability to stay permanently in study area with missing periods less 
than 3 months 
- Ability and willingness to participate in the study and to comply with 
all scheduled follow-up visits. 
- Written informed consent or assent provided by the patient and/or 
parent/guardian/spouse. 
- Haemoglobin level ≥7 g/dl, no sign of other illness or malnutrition, no 
pregnancy 
  
Patients, fulfilling the following criteria, were not eligible for this study: 
 
- Patients with signs and symptoms of severe/complicated malaria 
requiring parenteral treatment according to the World Health 
Organisation Criteria 2000 (16).  
- Severe vomiting described as more than three times in the 24 hours 
before inclusion in the study or inability to tolerate oral treatment or 
severe diarrhoea defined as 3 or more watery stools per day.  
- Known history or evidence of clinically significant syndromes such as 
cardiovascular (including arrhythmia, QTc interval greater or equal to 
450 milliseconds (QTC of ≤ 450 msec with either Bazett or 
Fridericia’s correction was acceptable)), history of jaundice, hepatic, 
respiratory (including active tuberculosis), renal, gastrointestinal, 
immunological (including active HIV-AIDS), neurological (including 
auditory), endocrine, infectious, malignancy, psychiatric  (active 
depression, generalised anxiety, psychosis, recent history of 
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depression, schizophrenia or other major psychiatric disorders), history 
of convulsions or other abnormality (including recent head trauma). 
- Hb < 7 g/dL. 
- The presence of febrile conditions caused by diseases other than 
malaria at the first inclusion as well as cases for whom oral treatment 
is not possible for the subsequent episodes. 
- Known history of hypersensitivity, allergic or adverse reactions to 
study drugs.  
- Documented use of any other antimalarial agent, including traditional 
medicines, within 2 weeks before the start of the study. 
- Female patients of child-bearing potential (≥12 year-old) must be 
neither pregnant (as demonstrated by a negative pregnancy test) nor 
lactating, and must not be planning on becoming pregnant during each 
42 day period after treatment. 
- Received a trial drug within the past 4 weeks.  
- Known or suspected chronic alcohol abuse, more than three units/day 
in men and more than two units/day in women. 
- Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface 
antigen (HBsAg) or Hepatitis C antibody (HCV Ab). 
- Known positive for HIV antibody. 
- Known significant renal impairment as indicated by serum creatinine 
of more than 1.5 x ULN. 
 
2.1.5. Retreatment criteria with study drugs 
Participants fulfilling the above inclusion/exclusion criteria at the subsequent 
malaria attack during the passive follow-up period, or at, or after the day 28 scheduled 
active follow-up, were re-treated with the same ACT allocated at the initial 
randomization.    
 
2.1.6. Temporary non-retreatment criteria with study drugs 
Participants were not re-treated with the same study drugs for new malaria 
episode if they met the following criteria: 
- One of the above non-inclusion criteria 
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-  Pf parasite density greater than 200,000 parasites/μl 
- Ongoing serious adverse events not related to study drug 
- Parasite infection before Day 28 scheduled follow-up visit 
- Use of any other antimalarial agent, other than the one used for malaria 
rescue treatment or severe malaria 
- Significant arrhythmia or prolonged QTc > 450 milliseconds during 
previous treatment or QTc > 450 milliseconds at the time of 
presentation or re-treatment. 
 
2.1.7. Criteria for permanent discontinuation of receiving study drug or withdrawal 
from the study. 
Patients, which had any additional study drug treatment, or were withdrawn 
from the survey, if any of the following criteria were met: 
- SAE related to study drug 
- Hypersensitivity, allergy to study drug 
- Sustained prolongation of QTc (>450 msec) related to treatment 
- Active chronic Hepatitis B or Hepatitis C. 
- Known positive for HIV. 
- Liver function [Alat levels] abnormality related to the study drug, an 
isolated increase of Alat more than 5 x ULN or Hy’s law (Alat >3 x 
ULN AND Total bili >2 x ULN). 
- Travel outside the study area for more than 3 months period. 
- Any other medical condition in the opinion of the investigator that may 
jeopardize the patient safety if she/he continues receiving the study 
drug. Such condition should be documented in details, and the study 
monitor should be notified immediately. 
- Consent withdrawal 
 
2.1.8. Concomitant treatment 
The administration of paracetamol/acetaminophen was allowed if the patient’s 
condition warranted it and was recorded in the Case Report Form (CRF). 
When early treatment failure or late clinical treatment failure occurred within 
28 days, an alternative treatment was used as rescue therapy (quinine for 7 days). Late 
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clinical treatment failure occurring within 28 days scheduled visit were treated with 
the randomized ACT.  
Molecules with antimalarial activity (such as co-trimoxazole, macrolides, 
tetracycline or doxycycline), were avoided if possible. When during follow-up, 
infections other than malaria required the administration of these antibiotics, they 
were clearly recorded and taken into account in the statistical analysis. On the other 
hand, beta-lactamines were recommended.   
All concomitant medications taken by the patient during the study, from the 
date of signature of the informed consent were recorded in the appropriate section of 
the CRF. 
 
2.1.9. Treatment 
PA, DHA-PPQ, ASAQ and AL were used during this sub-study. Each dose 
was administered with clean water under the supervision of study clinicians. As a 
precaution, patients were hospitalized during drug administration period. Doses were 
administered at fixed time point +/- 1 hour during the three-day administration period.  
Participants, who vomited one dose within 30 minutes of study drug 
administration, received an additional dose. If vomiting occurred between 30 and 60 
minutes, half a dose was administered. During the treatment phase, no more than two 
doses could be replaced. Each dose was administered according to body weight and 
the assigned treatment. 
The study drug administration scheme was as follows: 
Pyronaridine-artesunate (Pyramax®) 
PA was presented as a sachet (60:20 mg) for children and tablet (180:60 mg) 
for adult patients. It was administered once daily for 3 days as follow. 
- 1 sachet from 5 to < 8 kg 
- 2 sachets from 8 to < 15 kg 
- 3 sachets from 15 to < 20 kg 
- 1 tablet from 20 to < 24 kg 
- 2 tablets from 24 to < 45 kg 
- 3 tablets from 45 to < 65 kg 
- 4 tablets from 65 to < 90 kg  
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Dihydroartemisinin-piperaquine (Eurartesim®) 
DHA-PPQ was available as a tablet with two strengths (20:120 and 40:320 
mg) and was administered as follow. 
- 20:160 mg ½ tablet from 5 to < 7 kg 
- 20:160 mg 1 tablet from 7 to < 13 kg 
- 40:320 mg 1 tablet from 13 to < 24 kg 
- 40:320 mg 2 tablets from 24 to < 36 kg 
- 40:320 mg 3 tablets from 36 to < 75 kg 
- 40:320 mg 4 tablets from 75 to 100 kg  
 
Artemether-lumefantrine (Coartem-Dispersible® and Coartem®) 
AL was available as dispersible and crushed tablets with one strength 20:120 
mg. It was administered twice daily for 3 days. The doses were administrated as 
follow: dose 2 was given 8 hours after dose 1 administration. The administration time 
window for dose 2 was not higher than ± 1 hour. For the following doses at Hours 24, 
36, 48 and 60 (twice daily), the time window was not higher than ± 2 hours. 
- 1 dispersible tablet from 5 to <15 kg  
- 2 dispersible tablets from 15 to <25 kg  
- 3 tablets from 25 to <35 kg  
- 4 tablets for ≥ 35 kg 40:320 mg 2 tablets from 24 to < 36 kg  
 
Artesunate-amodiaquine (ASAQ-Winthrop®/Coarsucam®)  
ASAQ was used in 3 strength tablets and was administered once daily during 
three days as follow.  
- 25:67.5 mg: 1 tablet for ≥5 kg to <9 kg  
- 50:135 mg: 1 tablet for ≥9 kg to <18 kg  
- 100:270 mg: 1 tablet for ≥18 kg to <36 kg  
- 100:270 mg: 2 tablets for ≥36 kg  
   
2.1.10. Samples collection 
After enrolment on study, each patient was followed for 42 days or 63 days, 
depending on the study site. Patients were actively monitored (clinical and laboratory 
data were recorded) at day 0 (day of inclusion) day 1; 2; 3; 7; 14; 21; 28; 35; 42; and 
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63, and passively (Clinical and laboratory data were recorded in case of unscheduled 
visit) during the other days until day 63. Antimalarial drugs were administered from 
day 0 to day 2. Genotype samples were collected at day 0 and day of recurrence (if a 
patient came with parasitaemia before completing 63 days of follow-up). 
Pharmacokinetic samples were collected at day 7 (Figure 8).    
 
 
 
Figure 8: In vivo method 
Socio-demographic parameters: The variables measured for socio-demographic 
characteristics were: weight, height, age, gender, ethnicity.     
Clinical parameters: Variables, which were measured as clinical parameters included 
temperature, spleen size, blood pressure, heart rate, adverse event and concomitant treatment. 
These variables were measured at each active follow-up day. Electrocardiogram was done 
before initiation of the treatment at day 0 and day 2.   
Parasitological parameters consisted of asexual parasite (trophozoites) and sexual parasite 
(gametocytes) count.   
Hematological parameters measured were: total white blood cells and red blood cells count, 
haemoglobin, hematocrit, platelets, lymphocytes, monocytes, neutrophils, eosinophils and 
basophils count.      
Biochemical parameters: they were represented by creatinine, alanine aminotransferase 
(ALAT), aspartate aminotransferase (ASAT) and total bilirubin   
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2.1.11. Pharmacokinetic samples collection 
Plasma samples were collected from all the patients at any episode, on day 7 
of the ongoing follow-up (four days after administration of the last dose of the study 
drug). 
Briefly, around 1.2 ml of venous blood samples were collected in EDTA tube 
from patients treated with study drug (one of the ACTs) for uncomplicated malaria. S-
Monovette®, hematology (potassium EDTA), 4.9 ml, diameter 13 mm, length 90 mm, 
(SARSTEDT) tubes were used to avoid hemolysis during samples collection. Tubes 
were gently inverted for homogenisation and were centrifuged at 1,650 x g for 10 
minutes at room temperature within 15 minutes after sample collection. At least 500 
µl of plasma were stored in cryo-tube for drug quantification. Samples were kept 
directly at 4°C and transferred in -80°C within 24 hours on study sites or in our main 
laboratory in Bamako. Samples were shipped from Bamako to Heidelberg Germany 
on dry ice and kept at -80°C until analysis at the laboratory of the Department of 
Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg. 
 
2.1.12. Statistical analysis 
Data were entered and double-checked on Access. The data analysis was done 
using Stata version 12.1. Diagrams were designed using GraphPad Prism version 
5.0d.  
Chi-square test or Fischer exact test were used as appropriate to compare 
proportions. Mann-Whitney test or Kruskal-Wallis were used to compare medians of 
abnormally distributed variables. Spearman’s rank correlation test was used for 
correlation between two continuous variables. 
 
2.1.13. Ethical and deontological consideration   
The clinical protocol and the participant consent forms were approved by the 
ethics committee of the Faculty of Medicine, Pharmacist and Dentistry of Bamako 
before the start of the study. Each participant was free to participate in the study, and 
they were also free to withdraw for the study at any time. Written consent was to be 
given by each patient, or parent/guardian in the case of minors, after the receipt of 
detailed information on the study. Community permission was obtained before the 
start of the study.  
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2.2. Laboratory methods 
2.2.1. Materials 
2.2.1.1. Materials for genotyping 
- 0.5 μl Eppendorf tube 
- 0.2 μl PCR tube 
- 1.2 ml Eppendorf tube 
- 2 ml Eppendorf tube 
- 0.1 - 2.5 μl pipette and tips 
- 0.5 - 10 μl pipette and tips 
- 2 - 20 μl pipette and tips 
- 10 -100 μl pipette and tips 
- 20 - 200 μl pipette and tips 
- 100 - 1000 μl pipette and tips 
- 0.5 – 10 μl multichannel pipette 
- 10 - 100 μl multichannel pipette 
- Permanent marker 
- Gloves 
- Rack for PCR and Eppendorf tube 
- Filter paper 
- Vortex mixer 
- Neoblock (Neolab)  
- Mastercycler Eppendorf  
- Gel tank 
- Tank cover 
- Electrodes 
- Power supply 
- Casting tray 
- Combs 
- Erlenmer flasks 200 ml 
- Gel Doc XR imaging system (Bio-Rad) 
- Microamp optical 96 well reaction plate 
- 96 well plate retainer 
- 96 well plate base 
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- 96 well plate SEPTA 
- 4 capillaries 36 cm 
- 0.5 – 10 μl multichannel pipette 
- 10 – 100 μl multichannel pipette 
- ABI 3130 genetic analyzer 
- ABI 3130 and 3100-Avant capillary array 36 cm 
2.2.1.2. Materials for high-performance liquid chromatography 
- Ps- tube, screw cap, 12 ml, 16.8/100mm 
- Test tube, starwandig, ca. 100 x 16 mm 
- NeoSpenser 1 to 5 ml 
- Magnetic stirring bars 
- Ultrasonic Baths, mechanical timer with heater, M2800h-E 
- 0.1 - 2.5 μl pipette and tips 
- 0.5 - 10 μl pipette and tips 
- 2 - 20 μl pipette and tips 
- 10 -100 μl pipette and tips 
- 20 - 200 μl pipette and tips 
-100 - 1000 μl pipette and tips 
- PH-meter-Set with electrode 
- Centrifuge with refrigeration 
- Permanent cryomarker 
- Gloves 
- Rack for tubes 
 
2.2.2. Reagents 
2.2.2.1. Reagents for genotyping 
- Methanol 
- Distilled water 
- 10x Taq buffer with (NH4)2SO4 (Thermo Scientific) 
- 25 mM MgCl2 (Thermo Scientific) 
- diNucleotide TriPhosphate dNTP mix at 2 mM (Thermo Scientific) 
- Primers (Eurofins MWG/Operon) 
- Taq DNA polymerase 5 u/μl (Thermo Scientific) 
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- DNA 
- 70° alcohol  
- Distilled water 
- Ultrapure agarose  
- Tris base 
- Glacial acetic acid 
- EDTA (PH 8,0) 
- Deionized water 
- SYBR Safe (or Ethidium bromide)  
- 100 bp DNA ladder plus 
- DNA loading dye  
- Pop polymer (POP-7Tm 3130) 
- HiDiTm Formamide 
- Rox size standard 
- DNA 
- Water HPLC grade 
- Buffer (10x) with EDTA (3130 machine) 
- Matrix standard 
2.2.2.2. Reagents for high-performance liquid chromatography 
- Internal standard 
- Standard drug 
- Acid Boric 
- Water Cromasolv for HPLC 
- TEMED (-N,N,N,N TetraMethyl-Ethylene diamine) 
- Orthophosphoric acid 
- Dimethyl sulfoxide 
- 2-propanol HPLC grade 
- TerButyl Methyl Ether 
- Triethylamine 
- Potassium Hydrogen Phthalate 
- Sodium hydroxide solution 
- pH buffer solution pH7 
- pH buffer solution pH4 
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2.2.3. Methods for genotyping 
A validated high-throughput capillary electrophoresis with fluorescence 
detector was used to differentiate recrudescence from reinfection by analyzing msp2 
polymorphism. The method can detect a difference of two base pairs of genotype size 
[288]. It is also able to distinguish the different msp2 families. With this sensibility 
and specificity, it was possible to differentiate recrudescence from reinfection with a 
higher degree of accuracy. 
Parasite DNA extraction from filter paper was done by methanol extraction 
method [260]. After first amplification, five microliters of this product was used for 
nested amplification using family specific reverse primers coupled with different 
fluorescence dyes. The non-fluorescent–labeled forward primer is modified at the 5’ 
end by adding a 7-bp tail to avoid non-template–directed addition of a single 
nucleotide to the 3’ end of a blunt-end double-stranded DNA (“plus-A-
artefact”)[289].   
According to second amplifications’ DNA concentration, different dilutions 
were done before capillary electrophoresis. Results were interpreted according to the 
elaborated and validated criteria.  
Recrudescent samples with msp2 were reanalyzed with msp1. For specimens 
remaining recrudescent, a third amplification was done using the size polymorphic 
microsatellite ca1. These two last genes were amplified using simple nested PCR 
without capillary electrophoresis. The size polymorphism was detected by eye after 
agarose-gel electrophoresis.  
Samples deemed to be recrudescent with these three techniques were 
considered as true recrudescent samples in this study. 
2.2.3.1. Principle of the PCR and capillary electrophoresis methods: 
Fluorescent primers were designed for the second amplification of msp2. The 
reverse primers were coupled with a fluorescent dye. 6-FAM (6-Carboxyfluorescein) 
with its blue color after emission at wavelength 517 nm was combined with FC27 
family-specific primer, while VIC, with its green color, was coupled with 3D7 family-
specific primer.    
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Figure 9: Principle of fluorescent primer amplification 
 
 
 
  
 
Figure 10: The general principles of my PCR amplification methods 
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2.2.3.2. DNA Extraction by methanol: 
DNA was extracted from whole blood spotted and dried onto filter paper using 
the methanol extraction method [260]. The principle is to fix other constituents of the 
blood onto the filter paper with methanol and elute the DNA in sterile water under the 
action of the heat. Briefly, a small piece of filter paper was cut and embedded with 
whole blood (around 3 mm), then incubated in methanol for 15 min. The methanol 
was discarded and allowed to dry. A 50ul volume of distilled water was added; then 
boiled at 100°C for 15 min and vortexed each 5 minutes. 
Use the extracted DNA in distilled water for PCR or keep it at -20 or lower 
temperature until need.  
2.2.3.3. Amplification of msp2 gene: 
Nested PCR, coupled with capillary electrophoresis, was used to amplify 
merozoite surface protein 2 (msp2) gene.  
The process consisted of first amplifying the gene with primers which bind to 
the 3’ and 5’ conserved parts of the gene, resulting in amplification of all of the semi-
conserved and variable regions of msp2. A second amplification step used inner 
primers that are family specific. After running a gel of the second amplification, 
samples, which gave a band, are used for capillary electrophoresis.  
 
 Protocol for amplification: 
Primers sequence for msp2 amplification: 
  First amplification: 
S2 (forward primer): GAAGGTAATTAAAACATTGTC 
S3 (reverse primer) : GAGGGATGTTGCTGCTCCACAG 
Second amplification: 
S1 (forward primer): 7 bp tail-GCTTATAATATGAGTATAAGGAGAA 
M5 (reverse primer FC27 specific): 6FAM-GCATTGCCAGAACTTGAA 
N5 (reverse primer 3D7 specific): VIC-CTGAAGAGGTACTGGTAGA 
 
For PCRs, I used 10X Taq buffer with (NH4)2SO4, 25 mM Mgcl2, dNTP mix 
concentrated at 2 mM each, primers at 10 μM, Taq DNA polymerase (5 u/μl), (the 
final concentration of all the reagents was 1X). I used 5 μl of extracted DNA at first 
51 
 
amplification, and 1 μl of amplicon of the first amplication was used for second 
amplification. The final volume of the reaction was set at 50 μl.  
Mastercycler Eppendorf was used for DNA amplification and the cycling 
condition are in table1 and table 2 bellow. 
 
Table 1: Cycling conditions for msp2 the first amplification 
1 Initial denaturation 94 °C 5.00 minutes 
2 Denaturation 94 °C 30 seconds 
3 Annealing 55 °C 2 minutes 
4 Extension 70 °C 2 minutes 
5 Final extension 72 °C 7 minutes 
6 Keep at 4 °C  
Repeat step 2 to 4 for 30 times 
 
 
Table 2: Cycling conditions for msp2 the second amplification 
1 Initial denaturation 94 °C 2.00 minutes 
2 Denaturation 94 °C 30 seconds 
3 Annealing 50 °C 45 seconds 
4 Extension 70 °C 1.30 minutes 
5 Final extension 70 °C 10 minutes 
6 Keep at 4 °C  
Repeat step 2 to 4 for 44 times 
 
 
Gel revelation: 
To monitor the result of the amplification a gel was run of the amplified 
products. Positive samples were selected for capillary electrophoresis. 
Preparation of the gel: 
It consists of making 1% of agarose gel in 1x Tris Acetate EDTA (TAE) 
  
Preparation of 1x TAE: I prepare a stock solution of TAE concentrated at 
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50X. 
- Dissolve 242 g of Tris base in deionized water 
- Add 57.1 ml of glacial acetic acid 
- Add 100 ml of 500 mM of EDTA (PH: 8) solution 
- Bring the final volume up to 1 liter. 
- To have 1X, you dilute it with deionized water  
 
Preparation of 1% agarose gel: 
- Weight 1 g of agarose powder in 200 ml Erlenmeyer flask 
- Add 100 ml of TAE 1X 
- Boil 
- Add 10 μl of SYBR Safe or Ethidium bromide 
- Mix 
- Pour it into the tray with combs 
- When dried take out the combs 
- Put the tray with the gel in tank filled with 1X TAE 
- Mix the DNA with loading dye and load it in the well let by the combs  
- Cover the gel tank and run the samples for 30 at 100 millivolts.  
- Make the revelation under the gel photo machine 
 
Capillary electrophoresis: 
The principle is the separation of DNA fragment according to their sizes in the 
capillary filled with polymer. And the revelation is done according to the fluorescent 
dye link to each DNA. It is a high throughput technique capable of detecting a 
difference of two base pairs. 
Samples preparation for capillary electrophoresis: 
 Dilution of samples: According to the intensity of the band of the second 
amplification on the gel, I make a dilution of sample (1/200) in HPLC grade water.  
Preparation of samples:  
       For each sample: 
- Put 10 μl of Rox size standard in the well of the Microamp optical 96 
wells reaction plate. 
- Add 2.5 μl of the diluted product of the second PCR amplification  
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- Add 10 μl of HiDi 
- Cover the plate with the 96 wells plate SEPTA 
- Make sure that all of the liquid are at the bottom of the well not on the 
wall 
- Put the plate in the 96 wells plate base 
- And retains it with the 96 wells plate retainer 
- Put it into the capillary electrophoresis machine or keep it at -4°C until 
needed. 
 
2.2.3.4. Amplification of msp1 gene: 
Samples that remain recrudescent after msp2 analysis were reanalysed with 
msp1. The method consists of the amplification by nested PCR of the variable region 
(bloc 2) of the gene. The discrimination was done by size polymorphism and the 
visualization by eye. 
 
Primers sequence for msp1 amplification: 
First amplification: 
O1 : CACATGAAAGTTATCAAGAACTTGTC 
O2 : GTACGTCTAATTCATTTGCACG 
Second amplification: 
N1 : GCAGTATTGACAGGTTATGG 
N2 : GATTGAAAGGTATTTGAC 
 
Amplification of msp1 sequence was done with following reagents: 5X (Taq 
buffer + 7.5 mM Mgcl2), 10X dNTP mix concentrated at 2 mM each, 100X primers 
at 10 μM, Taq DNA polymerase (5 u/μl), (the final concentration of all the reagents 
was 1X). Five microliter of extracted DNA was used at first amplification, and 1 μl of 
amplicon of the first amplication was used for second amplification. The final volume 
of the reaction was set at 25 μl.  
Mastercycler Eppendorf was used for DNA amplification and the cycling 
condition are in table 3 and table 4. 
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Table 3: Cycling conditions for msp1 first amplification 
1 Initial denaturation 94 °C 3.00 minutes 
2 Denaturation 94 °C 25 seconds 
3 Annealing 50 °C 35 seconds 
4 Extension 68 °C 2.50 minutes 
5 Final extension 72 °C 3 minutes 
6 Keep at 4 °C  
         Repeat step 2 to 4 for 30 times 
 
Table 4: Cycling conditions for msp1 second amplification 
1 Initial denaturation 94 °C 2.00 minutes 
2 Denaturation 94 °C 30 seconds 
3 Annealing 50 °C 45 seconds 
4 Extension 70 °C 1.30 minutes 
5 Final extension 70 °C 10 minutes 
6 Keep at 4 °C Forever 
         Repeat step 2 to 4 for 44 times 
 
2.2.3.5. Amplification of microsatellite ca1 gene 
Samples that are still recrudescent after msp2 and msp1 correction were 
analyzed by the microsatellite ca1. That means that the discrimination was done using 
two size polymorphic genes that are under immune pressure (msp1 and msp2) and one 
without immune pressure ca1.  
The reagents and materials are the same like for msp1 except for the primers’ 
sequences and the cycling conditions.  
Primers sequences for ca1 amplification: 
  First amplification: 
ca1-1L : GCTGTAAAACGTGAACAACAAA 
ca1-1R : CAATTCTGCTTCAGTTGGATT 
Second amplification: 
ca1-L : ATTATGAACAATTCAGAC 
ca1-R : GTTGTTATAGCTAATGAG 
55 
 
Table 5: Cycling conditions for ca1 first amplification 
1 Initial denaturation 95 °C 5.00 minutes 
2 Denaturation 92 °C 30 seconds 
3 Annealing 45 °C 30 seconds 
4 Extension 65 °C 30 seconds 
5 Final extension 65 °C 5 minutes 
6 Keep at 4 °C  
Repeat step 2 to 4 for 44 times 
 
  
 
Table 6: Cycling conditions for ca1 second amplification 
1 Initial denaturation 95 °C 5.00 minutes 
2 Denaturation 92 °C 30 seconds 
3 Annealing 45 °C 30 seconds 
4 Extension 65 °C 30 seconds 
5 Final extension 65 °C 5 minutes 
6 Keep at 4 °C  
Repeat step 2 to 4 for 19 times 
 
2.2.3.6. Quality control of the PCRs: 
A negative control was included in all PCR samples to control for false 
positives and contamination. The negative control consisted of a tube without dried 
blood spot that otherwise replicated all of the extraction processes used for sample 
preparation. Briefly, I added methanol in this tube, evaporated the methanol, I added 
50 μl of water I used for the extraction and boiled it like the samples. This negative 
control was used during all of my amplifications, and it should remain negative after 
amplification. 
For control of the quality of my PCR amplifications, I used the reaction mix 
without the addition of DNA for the first amplification. This negative control was 
amplified at the second amplification too. I also used a second negative control for the 
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second amplification that was constituted with the reaction mix of the second 
amplification without DNA. 
In addition to the negative controls, positive controls for the PCR 
amplification were also included. These positive controls were from in vitro culture 
samples Pf 3D7 and D10 (FC27) from our lab. Each control had specific 
characteristics according to the gene amplification.  For example, for msp2 capillary 
electrophoresis, 3D7 electropherograms have a green color, which came from the 
fluorescent dye coupled with the primer, its size after second amplification is 267 bp. 
While D10 (FC27), with its blue color, which came from the coupled fluorescent dye, 
has a size of 358 bp after second amplification.   
 
2.2.4. Methods for high-performance liquid chromatography 
A developed and validated sensitive and specific high-performance liquid 
chromatography (HPLC) method with ultra-violet (UV) light detection (335 nm for 
lumefantrine and 340 nm for DEAQ) was used to quantify the day 7 concentration of 
these drugs in plasma. The limits of quantification were set at 20 ng/ml for 
lumefantrine and 24 ng/ml for DEAQ. 
The method was developed and validated for quantification of pyronaridine in 
plasma with UV detection at 275 nm and a limit of detection of 25ng/ml. After 
analyzing 40 patients’ samples, I found that my method was not able to quantify 
pyronaridine day 7 concentration in patients plasma, which is around 37ng/ml in 
whole blood[290]. Also a published data in rabbit showed that the blood plasma ratio 
of pyronaridine varies from 4.9 to 17.8. [161].  
   Briefly, i used a liquid-liquid extraction method to extract the drugs 
(pyronaridine, lumefantrine, and DEAQ) from 250 μl of plasma collected from 
malaria patient in Mali. After extraction, the upper organic phase (where the drug 
was) was dried under nitrogen gas. Two hundreds (200) μl of mobile phase were 
added to the dried drug, mixed, and 50 μl were injected in the HPLC machine (Figure 
11). 
 
    
57 
 
 
Figure 11: Summary of HPLC method 
 
 
2.2.4.1. Chemicals and Reagents: 
Pyronaridine, lumefantrine and DEAQ (AlsaChim) were gifts from 
WorldWide Antimalarial Resistance Network (WWARN), lumefantrine internal 
standard (a lumefantrine analogue TA3039, formula: C30H32BrCL2NO, molecular 
weight = 573.41; was a single diastereomer: E configuration of double bond see 
structure) is a gift from Novartis Pharma AG CH – 4002 Basel Switzerland. (4-((7-
chloro-4-quinolinyl) amino)-1-Pentanol), formula C14H17ClN2O, molecular weight 
= 264.75 was pyronaridine and DEAQ internal standard purchased from Toronto 
Research Chemicals Inc. High-purity water was prepared in our laboratory using 
TKA lab HP 6UV/UF system with a conductivity of 0.055µS/cm and a total organic 
carbon (TOC) of 3 – 10 ppb. TEMED (-N-N-N-N tetramethyl ethylene diamine) was 
purchased from SIGMA-ALDRICH (Germany). Orthophosphoric acid from NeoLAB 
(Germany), triethylamine (TEA) was purchased from MERCK. Acetonitrile gradient 
grade for liquid chromatography was from LiChrosolv. Acid Boric for analysis was 
purchased from EMSURE (MERCK); Potassium hydrogen phthalate for analysis 
from MERCK; tertbutyl methyl ether (TBME) from ENSURE, 0.1N Hydrochloric 
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acid, dimethylsulfoxide for analysis, 0.1N Sodium hydroxide and 1N sodium 
hydroxide TitriPUR were purchased from VWR (Merck Millipore) (Germany).  
For the preparation of the calibration curve standard, I used blank plasma from 
the outdated blood donation unit.     
 
 
 
Figure 12: Structure of standard dugs. 
 (a) lumefantrine, (b) lumefantrine internal standard TA3039, (c) 4-((7-chloro-
4-quinolinyl) amino)-1-Pentanol, (d) pyronaridine, (e) AQ, (f) DEAQ. 
 
2.2.4.2. Instrumentation 
The chromatographic analysis was carried out using a Hewlett Packard HP 
1050 Series HPLC system, equipped with a 1050 Series quaternary pump model 
79852A, 1050 series ultra violet detector mode 79853C, 1100 series vacuum degasser 
model model G1322A for HPLC systems HP, 1050 series autosampler model 
79855A.  
Separation of the analytes was carried out using Phenomenex Luna C18 100A 
column (250 X 4.6 mm, 5µm; USA), protected by phenomenex security guard 
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cartridges C18 (4 X 3 mm ID). The chromatographic data were analyzed on HP 1050 
Agilent ChemStation for LC and LC/MS system-Rev.A.10.02 software. 
 
2.2.4.3. Analytical conditions 
The mobile phase for pyronaridine quantification was constituted by a mixture 
of acetonitrile - of TEMED buffer at PH3.5 (82.5 : 17.5, volume/volume) at a flow 
rate of 0.7 ml/minute for 16 minutes.  
For lumefantrine quantification, the mobile phase was constituted with a 
mixture of acetonitrile – (TEMED buffer PH3.5 + 300 μl of TEA) (64 : 36, 
volume/volume) at a flow rate of 1 ml/min for 21 minutes. 
TEMED buffer preparation:  
- Take 950ml of HPLC grade water 
- Add 1500 μl of TEMED 
- Adjust the PH at 3.5 with orthophosphoric acid 
- Complete at 1000ml with HPLC grade water 
- Add 300 μl of TEA 
- Add 50 ml of Acetonitrile (to avoid bacterial contamination) 
- And mix 
 
The mobile phase for DEAQ quantification was constituted with the mixture 
of acetonitrile – TEMED buffer PH3.5 (14 : 86, volume/volume) at a flow rate of 1 
ml/min for 10 minutes 
 TEMED buffer preparation: 
- Take 950ml of HPLC grade water 
- Add 1500 μl of TEMED 
- Adjust the PH at 3.5 with orthophosphoric acid 
- Complete at 1000ml with HPLC grade water 
 
2.2.4.4. Extraction 
The following method was used to extract pyronaridine, lumefantrine, AQ and 
its metabolite DEAQ from plasma samples. 
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2.2.4.4.1. Preparation of Buffers 
 
Preparation of borate buffer PH 10: 
- Acid Boric: molecular weight 61.83g/mol 
- 1N NaOH 
- 0.1N NaOH 
o Solution A: to do 1liter (weigh 12.37g of boric acid, add 100ml 
of 1N NaOH and complete to 1liter with HPLC grade water) 
o Solution B: 0.1N NaOH 
o You can do: 
 59.6ml of solution A + 40.4 ml of solution B that give 
you PH10 (control with the PHmeter) 
 240 ml of solution A + 162 ml of solution B (control 
with the PHmeter) 
 298ml of solution A + 202 ml of solution B (control 
with the PHmeter) 
- The final concentration of Boric acid is 0.2M 
 
Preparation of phthalate buffer PH 3: 
Potassium Hydrogen Phthalate: C8H5KO4; molecular weight 204.23g/mol 
- To do 1liter of 0.1M  
- Weight 20.425g and dissolve it in HPLC grade water 
- Adjust the PH at 3 with 1N HCL. 
 
2.2.4.4.2. Extraction methods: 
 
- Put 250 µl of plasma samples in 12 ml tube 
- Add 25 µl of internal standard 
- Add 0.5 ml of Borate buffer pH10 for pyronaridine and DEAQ (0.3 ml 
of phthalate buffer pH3 for lumefantrine) 
- Vortex for 1 minute 
- Add 5 ml of TBME 
- Mix by tumbling for 20 minutes at 7rpm with the tumbling machine 
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- Centrifuge at 3000 G for 10 minutes for pyronaridine and DEAQ, and 
20 minutes for lumefantrine at 10 degree Celsius. 
- Transfer 4.5 ml of the upper organic phase in new tube 
- Dry under nitrogen gas at 40 ºC during 20 minutes 
- Add 200 µl of mobile phase 
- Vortex and inject 50 µl into the column.      
 
2.2.4.4.3. Preparation of standard drugs: 
 
- Pyronaridine standard was dissolved in water + 0.5% of 1N HCl to 
have the standard stock solution. Working solutions were obtained by 
serial dilution of the standard stock in water + 0.5% of 1N HCl to have 
a concentration range of 250 to 10000 ng/ml. To make the calibration 
standard, 25 µl of these working solutions were spiked in 250 µl of 
blank plasma to have a calibration samples with the concentration 
range from 25 to 1000 ng/ml. 
-  Pyronaridine stock solution for quality control (QC) was dissolved in 
water + 0.5% of 1N HCl and then serially diluted to have the QC 
working solutions. 25 µl of these solutions were spiked in 250 µl of 
blank plasma to have a final concentration of 80, 425 and 850 ng/ml  
- Lumefantrine standard was dissolved in methanol/HCl (90/10, v/v) to 
have a standard stock solution, which was kept frozen until need. The 
standard stock solutions were serially diluted with the suitable volume 
of methanol to obtain an individual working solution at a concentration 
range of 0.2 to 200 µg/ml and kept them at +4°C during the time of 
analysis. 25 µl of this working solution were diluted in 250 µl of blank 
plasma to make a calibration samples from 20 to 20,000 ng/ml. 
- Lumefantrine stock solution for quality control (QC) was dissolved in 
methanol/HCl (90/10, v/v) and serially diluted with methanol to have a 
working QC solutions, which were diluted in blank plasma to have a 
final concentration of 60, 6000 and 15000 ng/ml 
-  Lumefantrine internal standard TA3039 was dissolved in DMSO and 
used at the final concentration of 1μg/ml  
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- DEAQ, pyronaridine, and their internal standard (4-((7-chloro-4-
quinolinyl) amino)-1-Pentanol), the final concentration of IS 750 
ng/ml, were dissolved in water and kept frozen until need. The 
standard stock solution of DEAQ and pyronaridine were serially 
diluted with an appropriate volume of water to have working solutions 
at a concentration range of 0.2 to 20 µg/ml, and they were kept at 4°C 
during analysis. These working solutions were diluted in blank plasma 
to have a calibration samples range from 20 to 2000 ng/ml. 
- DEAQ QC stock solution was dissolved in water and serially diluted 
with water to have the working solution. These working solutions were 
diluted in blank plasma to have a final QC concentration of 60, 775 
and 1600 ng/ml. 
 
 
2.2.4.5. Quantification 
The quantification was done using the internal standard method. Two sets of 
calibrators were used to measure the level of calibration: one at the beginning and the 
other at the end. For elimination of probable memory effect after the high calibration 
level of lumefantrine, two blanks samples were analyzed instantaneously.  Seven 
calibration points were used to construct the calibration curve, with the peak area ratio 
of the drugs to IS, versus the concentration of the respective drugs in each standard 
sample. 
 
2.2.4.6.1. Analytical method validation 
Methods were validated according to the US Food and Drugs Administration 
(FDA) recommendations [291] and the European Medicines Agency guidelines. 
 
- Accuracy, Precision and Lower limit of quantification  
Accuracy and precision were determined using a replicate analysis (6 times) of 
quality control samples at low, intermediate and high concentration, and at the lower 
limit of quantification, which was 3 times lower than the concentration of the lower 
QC sample. This run was repeated on three different days, with the daily calibration 
curve to determine the concentration in each sample. The coefficient of variations 
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(CV%) within run (intra-assay), and between different runs (inter-assays) were 
calculated and reported as precision. The accuracy was described as a bias or the 
deviation of the true concentration from the measured one. 
 
- Stability of drugs 
Drugs’ stability was evaluated after three freeze-thaw cycles. The three frozen 
QC samples were thawed at room temperature for 4 hours and froze at -20°C for 24 
hours. The concentrations were measured before the first freezing and after the third 
freezing. For stability issues for each batch the QC samples concentration at the 
beginning were compared to the one at the end of the batch.  The stability was also 
measured after leaving samples at room temperature for 24h.    
 
- Extraction recovery 
The recovery of the drugs and the internal standard was measured at different 
QC concentration. The mean area obtained after extraction (N = 6), was divided by 
the mean area after direct injection (N = 3), and this result was then multiplied by 
100.  
 
- Selectivity 
The selectivity of the different methods was assessed using plasma from six 
different sources. The interference of these plasmas was evaluated with the low limit 
of quantification. Interference with other antimalarial drugs (CQ, sulfadoxine, 
pyrimethamine, mefloquine) and possible concomitant treatment drugs (paracetamol) 
was also assessed. 
 
- Memory effect 
The memory effect or carry-over was assessed after injection of the high 
concentration of the calibration standard. Blank injection constituted with mobile 
phase was immediately done after the injection of the high concentration. And if there 
was a peak at the indicated retention time, the percentage of its area was compared to 
the area of the high concentration.      
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2.2.4.6.2. Revalidation of N-desethylamodiaquine method 
The method for quantification of AQ and DEAQ was developed and validated 
by the laboratory of the Department of Clinical Pharmacology and 
Pharmacoepidemiology, of the University of Heidelberg before the start of this PhD 
thesis. For utilization of this method to quantify DEAQ concentration, the method has 
been revalidated. Accuracy and precision were determined using a replicate analysis 
(6 times) of quality control samples at low, intermediate, high concentration and the 
lower limit of quantification. 
 
2.2.4.6.3. Validation of the methods during patients’ samples analysis 
Precision and accuracy of QC samples during patients’ samples analysis were 
evaluated for all of the methods. This precision and accuracy should not exceed 15% 
 
2.2.4.6.4. Clinical sample quantification 
Sensitive and specific high-performance liquid chromatography methods were 
developed and validated according to FDA guidance to quantify DEAQ and 
lumefantrine in plasma collected from uncomplicated malaria patients treated with 
ASAQ or AL.   
Samples were kept at -80°C until the day of analysis. They were thawed at 
room temperature, and 250 μl were used for drug quantification. Methods for 
quantification of the two drugs are described in the upper chapter. 
Briefly, after liquid-liquid extraction using borate buffer at PH10 and TBME 
for DEAQ and phthalate buffer PH3 and ethyl acetate for lumefantrine, the organic 
phase, which contains the drug were dried under nitrogen gas at 40°C after 
centrifugation. 200 μl of mobile phase (acetonitrile – TEMED buffer PH3.5, 14 : 86, 
volume/volume for DEAQ) and (33% of TEMED buffer at PH: 3.5 with 
Orthophosphoric acid + 300μl of TriEthylAmine  (solvent A) and 67% of Acetonitrile 
(solvent B) v/v for lumefantrine) were added into the dried tube and then mixed, and 
50 μl were injected into the column.    
For each batch, a new calibration curve was made, and two sets of the three 
quality control samples were run. Lower QC concentration samples were run just after 
the calibration curve at the beginning of patients’ samples analysis, medium QC 
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concentration samples were run in the middle of the analysis and high QC 
concentration samples were run at the end of the analysis. 
 
2.2.5. Data management and analysis 
Data were entered and double-checked on access. The data analysis was done 
using Stata version 12.1. Diagrams were designed using GraphPad Prism version 
5.0d.  
Chi-square test or Fischer exact test were used as appropriate to compare 
proportions. Mann-Whitney test or Kruskal-Wallis test was used as appropriate to 
compare medians of abnormally distributed parameters 
 
2.3. Outcomes and statistical analysis methods 
I first computed the proportion of patients without subsequent episode by day 
28 and 42 in each treatment arm, defined as the absence of Pf parasite by day 28 or 42 
of follow-up at each episode in each treatment arm. I also measured these proportions 
after molecular correction to differentiate true recrudescence from cases of 
reinfection. Other efficacy outcomes were the post-treatment prophylaxis of each arm 
during the two years of follow-up measured by the risk of parasite recurrence.   
For safety outcomes, the change in QTc (corrected QT interval) from baseline 
to day 2 (4 to 6 hours after the last dose) was evaluated. Twelve-lead ECG was used 
to measure the QT-interval, which was corrected for heart rate (using Fridericia 
formula). A change greater than 30 ms was considered as abnormal [292]. The second 
safety variable was the change in ALAT between baseline and day 3 with abnormal 
ALAT at day 3 defined by the laboratory reference ranges of Malaria Research and 
Training Center (MRTC) in Mali. Was considered abnormal if ALAT level was 
higher than 61 IU/L in adult patients (age > 14 years), or greater than 53.4 IU/L in 6 
to 14 years’ age group, or greater than 50 IU/L in less than 6 years’ patients. 
For pharmacokinetic outcomes, HPLC methods were developed and validated 
to quantify lumefantrine and DEAQ in plasma. The accumulation of lumefantrine and 
DEAQ in the study population was evaluated by comparing day 7 concentration of 
these drugs between the first episode and patients receiving subsequent treatment 
between 26 and 45 days and patients receiving subsequent treatment after 45 days. 
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The role of day 7 drug concentration in protection against early reinfection 
was evaluated by Cox univariate and multivariate modeling of factors associated with 
risk of parasite recurrence by day 28 and 42. 
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3 Results: 
 
3.1. Clinical study findings 
  
3.1.1. Study profile and baseline characteristics 
Figure 13 shows the profile of my sub-study. A total 1792 participants were 
included in this sub-study with 448 in the DHA-PPQ arm, 449 in the PA arm, 671 in 
the AL arm and 224 in the ASAQ arm. Ninety four point nine percent (94.9%) of 
participants successfully completed the two-year follow-up in DHA-PPQ arm, 90.6% 
in the PA arm, 95.1% in the ASAQ arm and 94.9% in the AL arm. Participants were 
treated with ASAQ in Bougoula-Hameau only.  
In the DHA-PPQ arm, 23 participants did not complete the two-year follow-up 
period. Among these 23 participants, there was one death, a 2 year old girl who died 
from unknown causes 166 days after her inclusion on study.  
In the PA arm, 42 participants did not complete the two-year follow-up period. 
Of these, there were two deaths. The first was a 4 year-old girl, who died 188 days 
after her inclusion on study. An 8 year old boy also died 42 days after his inclusion on 
study after falling from a tree.    
For the eleven participants in total who did not complete the two years of 
follow-up in the ASAQ arm, 8 withdrew consent, 2 were lost to follow-up, and the 
last was for another undefined reason.  
For the 34 participants in the AL arm, who did not complete the two years of 
follow-up, there were 2 deaths. The first was a 16 year old girl, who died 82 days 
after her inclusion into the study and the cause of the death was due to another disease 
not related to malaria or the antimalarial drugs. The second death was of a 7 year old 
male, who died 28 days after his inclusion into the study after he fell into a well. 
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Figure 13: Study profile.  
(DHA-PPQ) dihydroartemisinin-piperaquine. (PA) pyronaridine-artesunate. (ASAQ) 
artesunate-amodiaquine. (AL) artemether-lumefantrine.  
  
Baseline characteristics of participants at inclusion appear in Table 7. 
Participants aged 5 to 9 years old were the most represented in DHA-PPQ, ASAQ and 
AL treatment arms, with an incidence of 42.19%, 52.23%, and 33.98%, respectively.  
During the two years of follow-up, of the 449 participants included in the PA 
arm, 301 (67.04%) were re-treated with the same drug for 746 episodes with 6 
patients re-treated 9 times. Of the 448 participants included in DHA-PPQ arm, 317 
(70.76%) were re-treated with the same drug for 824 episodes with 3 patients re-
treated 9 times and one patient eleven times. In ASAQ arm, of the 224 participants 
included, 205 (91.52%) were re-treated during the two-year follow-up period for 837 
episodes with 8 patients re-treated 9 times, seven patients 10 times, one patient 11 
times and one patient 13 times. Of the 671 participants in AL arm, 453 (67.51%) were 
re-treated for 1061 episodes with one patient retreated 9 times, two patients 10 times 
and one patient 11 times (Table 8).  
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Table 7: Characteristics of participants at inclusion into different 
treatment arm. Age is expressed in year. P. falciparum: median (/μl) (Q1 – Q3) 
represents median number of asexual forms of parasites per μl with the interquartile 
range. 
 
 
 
Table 8: Number of episodes per treatment arm. The proportion of patients 
at each episode (E2, E3, E4 … E13) in each treatment arm was calculated by dividing 
the number of patients at that episode by the number at the first episode (E1).  
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3.1.2. Treatment response by episode at day 28 and 42 of follow-up shows the 
intensity of malaria exposure/recurrence by treatment arm 
The proportion of patients without subsequent episodes of malaria or 
Plasmodium sp. asexual parasitaemia relapse by day 28 of follow-up in the PA arm 
was lower at episode 4 (92.71%) than episode 1, 2, 3 and 5 (p = 0.023). In the DHA-
PPQ arm there was no difference between episodes. By comparison, in the ASAQ 
arm the lowest efficacies were recorded at episodes 2 and 3 with 85.93% and 85.29% 
efficacy, respectively and the highest efficacy at episode 1 with 94.64% (p = 0.028). 
In the AL arm, the lowest efficacy was observed at episode 4 (79.86%), but there was 
no statistical difference compared to other episodes (p = 0.051) (Table 9).  
At 42 days of follow-up, the number of patients without subsequent treatment 
episodes decreased from episode 1 to episode ≥ 6 in the PA arm. This may have 
occurred as a result of selection of tolerant parasite by this treatment arm or it may be 
due to the repeated malaria exposure. Participants who are more exposed to malaria 
may do more episodes. The same trend of decreased efficacy was observed from 
episode 1 to episode ≥ 6 in the DHA-PPQ arm, but the decrease was not significant in 
this treatment arm. Contrasting with this scenario, in the ASAQ arm, as for day 28 of 
follow-up, episode 1 with 77.23% of efficacy had the higher number of patients 
without subsequent episode at day 42 compared to others episodes (p < 0.001). In AL 
arm there was no decrease in the efficacy from episode 1 to episode 5. The lowest 
efficacy was recorded at episode ≥ 6 with a proportion of (52.5%) (p = 0.034) (Table 
10).  
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Table 9: Proportion of patients without subsequent episode by treatment arm 
and by episode at day 28 of follow-up. In PA arm episodes 6 – 9 were 
gathered together as episode ≥ E6. In DHA-PPQ and AL arm episodes 6 – 11 
were gathered together as episode ≥ E6. In ASAQ arm, episodes 6 – 13 were 
gathered together to form episode ≥ E6 
 
 
 
Table 10: Proportion of patients without subsequent episode by treatment arm 
and by episode at day 42 of follow-up. In PA arm episodes 6 – 9 were 
gathered together as episode ≥ E6. In DHA-PPQ and AL arm episodes 6 – 11 
were gathered together as episode ≥ E6. In ASAQ arm, episodes 6 – 13 were 
gathered together to form episode ≥ E6 
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3.1.3. Treatment response by arm at day 28 and 42 of follow-up shows the intensity 
of malaria exposure/recurrence by site:  
Sotuba, with its lower transmission intensity, had the higher proportion of 
patients without subsequent episode at day 28 and 42 in all of the treatment arms. 
DHA-PPQ and PA had an efficacy of more than 96% at day 28 and 42. The 
proportion of patients without subsequent episode in AL arm in Sotuba was 94.84% at 
day 28 and 87.76% at day 42 of follow-up. The proportions of patients without 
subsequent episode in Kollé and Bougoula Hameau were not statistically different 
except at day 42 in PA and AL arms with the lower proportion in Kollé (Table 11). 
In general, a drastic decrease in the proportion of patients without subsequent 
episodes was observed from day 28 to day 42 of follow-up in each treatment arm and 
at each study site. 
 
 
Table 11: Efficacy of treatment arms at day 28 and 42 of follow-up by site 
(ASAQ was implemented in Bougoula Hameau only) 
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3.1.4. Distribution of the proportion of patients without subsequent episode by 
treatment arm and by age group at day 28 and 42 of follow-up: 
Except for the ASAQ arm and DHA-PPQ arm at day 28 of follow-up, my 
results showed an increase in the proportion of patients without subsequent episode at 
day 28 and 42 with age groups in PA, DHA-PPQ and AL arms (p < 0.005). In DHA-
PPQ arm, at day 28 of follow-up, there was no difference between age groups. Age 
group ≥ 15 years had a higher proportion of patients without subsequent episode at 
day 28 of follow-up respectively 100% in PA, DHA-PPQ and ASAQ arms, and 
96.35% in AL arm. Patients in the lower age group (< 5 years) had a lower proportion 
of patients without a subsequent episode. There was no difference between age groups 
concerning the percentage of patients without subsequent episode by day 28 in ASAQ 
arm (Table 12). 
In ASAQ arm, except for age group ≥ 15, the proportion of patients without 
subsequent episode by day 42 of follow-up was higher in under 5 years old age group 
than the others (p = 0.004). Age group 5 - < 10 years had a lower proportion of 
patients without subsequent episode at day 42 of follow-up compared to the others 
age groups (Table 12). 
 
Table 12: Patients without subsequent episode at day 28 and 42 of follow-up 
by treatment arm and by age group 
 
 
74 
 
3.1.5. Safety of the treatment arms 
I looked for two major adverse events during this study. The first one was the 
cardiotoxicity defined by an abnormal QTc at day 2 (4 to 6 hours after the last dose of 
treatment) as compared to QTc at baseline (day 0). Cases with a QTc higher than 30 
milliseconds were considered abnormal. The other adverse event of interest I 
monitored was the hepatotoxicity defined by the abnormal level of alanine 
aminotransferase (ALAT) concentration in patients at day 3. As stipulated by 
laboratory reference ranges of Malaria Research and Training Center (MRTC) in 
Mali.  
Was considered abnormal if ALAT level was higher than: 
- 61 IU/L in adult patients (age > 14 years) 
- 53.4 IU/L in 6 to 14 years’ age group  
- 50 IU/L in less than 6 years’ patients  
Table 13 shows the proportion of patients with abnormal ALAT and QTc in 
the treatment arms. The higher proportion of abnormal ALAT was in PA arm (6.42%) 
and the lower in ASAQ arm (2.77%). The higher proportion of patients with abnormal 
QTc was reported in DHA-PPQ arm (30.37%) and the lower in PA arm (8.60%).  
 
 
Table 13: Level of abnormal ALAT and QTc in different treatment arms  
 PA 
% (n/N) 
DHA-PPQ 
% (n/N) 
ASAQ 
% (n/N) 
AL 
% (n/N)  value 
Abnormal 
ALAT 
6.42 (70/1090) 3.76 (42/1116) 2.77 (27/974) 3.15 (50/1589) <0.001 
Abnormal 
QTc 
8.60 (93/1081) 30.37 (338/1113) 22.05(217/987) 12.74(200/1570) <0.001 
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3.2. Genotype results 
A total of 1027 pairs of recrudescent patient blood samples were analysed at 
day 42 of follow-up. There were 179 pairs in PA arm, 36 in DHA-PPQ arm, 330 in 
ASAQ arm and 482 in AL arm. To discriminate cases of reinfection from 
recrudescent parasites, I used Pf size polymorphic genes (msp2, msp1, and ca1).  
For discriminating parasites with msp2, I used a nested PCR for its 
amplification coupled with capillary electrophoresis for its revelation. This method of 
evaluation allowed me to better characterize the multiplicity of infection in the study 
population.  
 
3.2.1. Genetic diversity of parasites in study sites  
With msp2 capillary electrophoresis, I found that the multiplicity of infection 
was as high as 9, meaning that a patient can harbor up to 9 different clones of parasite 
at the same time as shown in (Figure 14, d). The mean multiplicity of infection was 
4.7 in the study population. 
My results showed a high genetic diversity of Pf in the study area. The major 
allele was FC27 (336 bp) with a frequency of 11.7%; followed by FC27 (371 bp and 
417 bp) observed respectively in 7.8 and 6.8% of case. The most frequent 3D7 allele 
was 3D7 (282 bp). The diversity of 3D7 was higher than the one of FC27 in my study 
area (Figure 15).  
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Figure 14: Electropherograms of the msp2 capillary electrophoresis. 
 (a) negative control of the extraction; (b) 3D7 family’s positive control (green 
color); (c) FC27 family’s positive control (blue color); (d) sample from one of 
the patients included in this study. This patient harbored 4 alleles of the 3D7 
family green colored and 5 alleles of the FC27 family blue colored. Red peaks 
are the size standards (rox); green peaks are 3D7 family alleles; and blue 
peaks are FC27 family alleles.  
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Figure 15: msp2 genetic diversity in my study sites in percent. 
 FC27 allele 336 is the most frequent with 11.7%. OTHER represents alleles 
which frequency was less than 0.9%  
 
 
3.2.2. Treatment response by arms after molecular correction 
In antimalarial drug clinical trials, estimation of true drug efficacy is done by 
identifying recurrent infections detected after drug treatment as recrudescent parasites 
or as new infection coming from the liver. This categorisation of recurrent infection is 
done by comparing the size of the length-polymorphic molecular markers before and 
after treatment. If the sizes of the amplicons at day 0 (before treatment) differ from 
the one at day of failure (recurrence), the recurrent infection is considered as a new 
infection, but if the sizes are the same, these are categorized as recrudescent infections 
and are considered as true treatment failures. Discrimination of recrudescent parasites 
from reinfection in this work was done sequentially. Firstly, the most length-
polymorphic molecular marker msp2 were used on all of the recurrent infection 
samples. Secondly, all samples that were identified as recrudescent by msp2 were 
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analysed with msp1. Lastly, the remaining recrudescent parasites were analysed with 
ca1.  
The antimalarial drugs used in this study were highly efficacious, with all 
demonstrating more than 99% efficacy after molecular correction. DHA-PPQ and 
ASAQ were 100% efficacious; and all of the recurrent parasites in these treatment 
arms were cases of reinfection. For PA, there were 3 cases of recrudescence at day 42 
of follow-up. In the AL arm, there were 7 cases of recrudescent infections. Table 14 
shows the characteristics of patients with the recrudescent parasites in the AL arm. 
These patients did not share any particular characteristics of note except that the 
majority were from the Kollé site. Further investigation will determine if drug 
concentration played a role in the recrudescence of infection in these patients. 
 
 
Table 14: Characteristics of patients with recrudescent parasites after 
molecular correction in AL arm. Day 7 lumefantrine concentration was 
quantified in patients with recrudescence of infection.   
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3.3. Development and validation of HPLC methods for the 
quantification of lumefantrine, N-desethylamodiaquine, and 
pyronaridine in plasma. 
Methods have been developed and validated for quantification of lumefantrine 
and pyronaridine in plasma. 
For DEAQ, there was already a developed and validated method for its 
quantification in plasma in the pharmacokinetic lab. For my study, I revalidated the 
method before quantification of my samples. 
The methods for quantification of lumefantrine and DEAQ were sensitive and 
specifics to be applied for quantification of day 7 concentration of these drugs in 
malaria patients. 
Figure 16 shows electropherograms for lumefantrine, DEAQ, and their ISs. 
There was a good separation between drugs and IS. The retention times for 
lumefantrine and its IS were respectively 13.8 minutes and 17.7 minutes. DEAQ had 
a retention time of 6.3 minutes, and its IS 4.4 minutes. For pyronaridine, it was 7 
minutes while its IS come out at 14.4 minutes. 
There were no retention time variations with direct injection or spiked samples 
or drugs obtained from malaria patients. 
IS used for the quantification of pyronaridine and DEAQ had structural 
similarity with these drugs. For lumefantrine, I tested three of its analogs: two were a 
gift from Novartis (TA3099 and TA 2006-12-14K2) and one was already used as IS 
for lumefantrine quantification [293]. TA3099 was the one, which didn’t interfere 
with any other drug or endogenous peaks. The other two analogs interfered with 
endogenous peaks under selected conditions.   
All of the methods gave excellent linearity. Calibrations curve’s coefficients 
of correlation were always higher than 0.997 (Figure 17).  
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Figure 16: Electropherograms of quantified drugs. 
 (a) N-desethylamodiaquine, (b) lumefantrine, from my patients and their internal 
standards. DEAQ has a retention time of 6.3 minutes its IS come at 4.4 minutes. 
While lumefantrine has a retention time of 13.8 minutes, its IS comes at 17.7 minutes. 
 
 
 
Figure 17: Lumefantrine calibration curve with R-Square = 0.9987 
 
Within-day and between days’ coefficients of variation of both methods for 
pyronaridine and lumefantrine were always less than 12%, showing that the methods 
have a good precision. The deviations of the true concentration from the measured 
concentration of the QCs samples were always between 90 and 110% for 
pyronaridine and lumefantrine confirming the good accuracy of the methods. The 
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Intra and inter-batch variations of the limits of quantification were less than 10% 
(Table 15 and 16). 
Extraction recovery for pyronaridine, lumefantrine, and their internal 
standards was excellent. Recoveries from plasma were higher than 75% for all of the 
drugs and ISs. The recovery of lumefantrine was higher than 80% at differents QC 
samples. For pyronaridine, the recovery was higher than 90%. The recovery for 
lumefantrine IS (concentration = 1000ng/ml) was 76.3±3 in percent. Moreover, the 
recovery of the IS of pyronaridine and DEAQ at the concentration of 750 ng/ml was 
91.7 ± 2 in percent. 
No other antimalarial drugs interfered with the peaks of my drugs. Neither the 
main concomitant drug (paracetamol) nor the endogenous substances interfered with 
the peaks.  
Injection of the mobile phase directly after the high drug concentration 
showed that there was no carry over for the methods.    
 
Table 15: Lumefantrine Intra and inter-day precision, and accuracy 
Cspiked 
(ng/ml) 
Cfound mean±S.D 
(ng/ml) 
Withing-asay 
CV (%) 
Between-
assay CV (%) 
Bias 
(%) 
20 21.8 ± 1.3 6.3 6.1 9.3 
60 54.9 ±  3.9 9.2 11.5 -8.4 
6000 5973.4 ± 162.3 2.3 2.7 -0.4 
15000 14982.6 ± 291 1.3 1.9 -0.1 
  
 
Table 16: Pyronaridine Intra and inter-day precision, and accuracy 
Cspiked 
(ng/ml) 
Cfound mean±S.D 
(ng/ml) 
Withing-assay 
CV (%) 
Between-assay 
CV (%) 
Bias (%) 
25 25.7 ± 1.8 2.8 7.0 2.4 
80 76.6 ± 2.2 3.2 2.8 -4.3 
418 415 ± 18.9 1.1 4.6 -2.3 
806 845.6 ± 32.9 3.9 3.9 -0.5 
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DEAQ method has been revalidated successfully with a withing-assay 
coefficient of variation of 3% at 60 ng/ml; 2.8% at 775 ng/ml and 2.8% at 1600 
ng/ml. The method was accurate and precise at the different quality control 
concentrations.   
 Table 17 and 18 showed the precision and accuracy of quality control samples 
used in the analysis of clinical samples collected from uncomplicated malaria patients 
at day 7 of follow-up after treatment with AL or ASAQ. A total of 26 batches with 
two replicates of each QC samples were used to quantify lumefantrine concentrations 
in patients. From these 52 replicates at each QC concentration only one in high 
concentration QC was out of the 15% concentration variation recommended (spiked 
concentration 15000 ng/ml, the concentration found 17255.9 ng/ml). 
For DEAQ quantification, I used 11 batches with two replicates of each QC 
samples. None of the measured QC concentrations varied more than 10% from the 
spiked concentrations. 
The mean variations of precision and accuracy were always less than 10%.     
For pyronaridine, after quantification of 40 samples collected from 
uncomplicated malaria patients at day 7 of follow-up (4 days after the last dose) I 
found that pyronaridine concentrations were always under the limit of quantification, 
which was set at 25 ng/ml. The method developed and validated was not able to 
quantify pyronaridine concentration in malaria patients at day 7 of follow-up. 
 
Table 17: Validation of lumefantrine quantification method during patients’ 
samples analysis 
Cspiked 
 (ng/ml) 
 
Cfound 
mean±S.D (ng/ml) 
(N) 
CV (%) Accuracy 
60 60.8 ± 2.2 (52) 3.7 101.3 
6000 6075.1 ± 190.9 (51) 3.1 101.3 
15000 15471.4 ± 650.7 (52) 4.2 103.1 
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Table 18: Validation of N-desethylamodiaquine quantification method during 
patients’ samples analysis 
Cspiked 
 (ng/ml) 
 
Cfound 
mean±S.D (ng/ml) 
(N) 
CV (%) Accuracy 
60 57.6 ± 2.1 (22) 3.6 96.1 
775 734.2 ± 33.8 (22) 4.6 94.7 
1600 1604.5 ± 46.4 (22) 2.9 100.3 
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3.4. Pharmacokinetic of lumefantrine and N-desethylamodiaquine at 
day 7 of follow-up 
 
3.4.1. Number of episodes and baseline characteristics in patients with quantified 
drug concentrations 
Table 19 shows the number of samples analyzed by HPLC in each treatment 
arm by episode. In total lumefantrine concentration were quantified at day 7 in 1100 
samples collected from 659 patients with uncomplicated malaria treated with AL. 
DEAQ was quantified in 749 samples taken from 217 patients treated with ASAQ.   
Episodes’ baseline characteristics of patients are summarized in Table 20. 
There was no difference between mean ages by sex in AL or ASAQ arm. Age group 5 
– 9 years contributed to the maximum number of samples. This age group was the 
most affected by malaria in the two treatments arm.  
Sotuba site, where the transmission is low contributed to the maximum 
number of adult patients 64.7% and Bougoula-Hameau with 29.7%.      
  
Table 19: Number of samples analyzed by episode in different treatment 
arm to quantify lumefantrine and N-desethylamodiaquine 
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Table 20: Episodes’ baseline characteristics of patients with drug concentration 
Characteristics Artemether-lumefantrine Artesunate-amodiaquine 
 Male Female Male Female 
Mean age ±SD 12.2 (8.5) 11.9 (9.3) 8.7 (3.1) 8.5 (2.9) 
Age category (n)     
< 5 years 80 60 45 30 
5 – 9  201 198 232 181 
10 – 14 128 124 143 92 
≥ 15 186 99 0 0 
Median temperature 37.8 37.6 37.3 37.2 
Pf: median (/µl) (Q1 – Q3) 17,980 
(3,060 – 46,400) 
21,110 
(3,380 – 47,920) 
19,580 
(1,620 – 45,200) 
14,400 
(1,520 – 34,900) 
 
 
3.4.2. Accumulation of lumefantrine and N-desethylamodiaquine in study population 
after repetitive treatment with the same drug: AL or ASAQ 
In the AL arm, I did not find any accumulation of lumefantrine in study 
population after repetitive treatment of patients with the same drug. There was no 
statistical difference in day 7 concentration of lumefantrine neither between episodes 
as shown in (Figure 18 a), nor between period at which patients received the 
subsequent treatment (Figure 19 a). Some patients received 10 times the same 
treatment during the two years period of follow-up. 
Repetitive treatment of uncomplicated malaria patients with ASAQ 
accumulated DEAQ in study population when patients received subsequent treatment 
in a short period. In the ASAQ arm, when the patient received a subsequent treatment 
of ASAQ in a period of 45 days, there was an accumulation of DEAQ in population 
as shown in (Figure 19 b). Patients, who received subsequent treatment between day 
26 and 45 had a high day 7 concentration of DEAQ when compared to the 
concentration at the first treatment or to the concentration from patients who received 
a subsequent treatment after 45 days.  
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 Figure 18: Lumefantrine and DEAQ day 7 concentration profile after 
repetitive treatment of a new episode of uncomplicated malaria with 
the same drug (AL or ASAQ). 
 (a) lumefantrine concentration, (b) DEAQ concentration, (E) episode. 
Number 1, 2, 3…are number of malaria episodes, in individual patients during 
the two-year follow-up period corresponding also to the number of time an 
individual patient received the same drug during the two years. 
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Figure 19: Day 7 concentrations variation according to the time of 
retreatment.     
(a) Lumefantrine did not accumulate in study population after repetitive 
treatment with AL. (b) DEAQ accumulates in patients receiving a second 
treatment with ASAQ in a period of 45 days.  
 
3.4.3.  Distribution of lumefantrine and N-desethylamodiaquine day 7 concentration 
by age group, sex and fever status before treatment 
Day 7 concentration of lumefantrine decreases with age. In my study 
population the lower median day 7 concentration of lumefantrine was measured in 
under 5 years’ patients (305.9 ng/ml (IQR: 207.3 – 491.5)) and the higher in more 
than 15 years (571.1 ng/ml (IQR: 378.8 – 850.9)). The increase of lumefantrine 
median day 7 concentration with age group was very highly significant (p < 0.0001). 
This association profile persisted even after normalisation of concentration by body 
weight and drug dose (p < 0.0001) (Figure 20 a). 
For DEAQ, there were no differences between medians of day 7 concentration 
by age group p = 0.1803 (Figure 20 b). 
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Figure 21 shows the distribution of lumefantrine and DEAQ day 7 
concentration by sex. Lumefantrine median concentration was 10.6% lower in female 
than male (p = 0.0093). Contrasting with this observation, DEAQ median 
concentrations in both sexes were comparable (p = 0.1598).  
Patients with fever at inclusion had lower day 7 median concentration of 
lumefantrine and DEAQ as compared to patients without fever with highly significant 
differences (p < 0.001) as shown in Figure 22.   
 
 
Figure 20: Day 7 concentrations distribution by age group. 
All of the patients in ASAQ arm were under 15 years old (b). Lumefantrine 
day 7 median concentration increased with age (a) but not DEAQ day 7 
median concentration after treatment of uncomplicated malaria patients with 
AL or ASAQ at first episode. The concentrations at E1 were used to avoid the 
effect of DEAQ accumulation. The lumefantrine concentration difference was 
statistically significant between age group of patients receiving AL (p < 
0.0001).   
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Figure 21: Day 7 concentration distribution by sex  
(a) lumefantrine, (b) DEAQ. Lumefantrine day 7 median concentration was 
higher in male patients compared to female after treatment of uncomplicated 
malaria with AL (a). While, there was no impact of sex on 
desethylamodiaquine day 7 concentration distribution after treatment of 
uncomplicated malaria patients with ASAQ (b). 
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Figure 22: Day 7 concentration distribution by fever status.  
Baseline fever had an impact on plasma drug concentration. Febrile patients at 
inclusion had a lower day 7 median concentration compared to non-febrile 
after treatment of uncomplicated malaria with AL (a). For DEAQ there was no 
difference of day 7 median concentrations between febrile and non-febrile 
patients at inclusion after treatment with ASAQ (b).  
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3.5. Pharmacodynamics of lumefantrine and N-desethylamodiaquine 
 
3.5.1. Relationship of lumefantrine and N-desethylamodiaquine day 7 concentrations 
with treatment response at day 28 and 42 
I looked at the protective effect (post-treatment prophylaxis) of lumefantrine 
and DEAQ day 7 concentrations at day 28 and 42 of follow-up after treatment of 
uncomplicated malaria patient with AL or ASAQ. 
The median concentration of lumefantrine at day 7 of follow-up was 36.7% 
higher in patients without subsequent episode before day 28 of follow-up than in 
patients who had subsequent episode p < 0.0001 (Figure 23 a). At day 42 of follow-up 
patients without subsequent episode had 7.6% higher lumefantrine day 7 median 
concentration compared to patients with subsequent episode p = 0.0102 (Figure 24 a) 
For DEAQ, there was no difference between day 7 median concentration of 
patients with or without subsequent episode at day 28 or 42 of follow-up.  
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Figure 23: Association of low day 7 concentration with parasite 
recurrence by day 28 of follow-up.  
(a) Lumefantrine day 7 concentration was lower in patients with recurrent 
parasitaemia before 28 days of follow-up as compared to those without 
recurrent parasitaemia after treatment with AL. (b) For DEAQ, there was no 
difference between day 7 concentration in patients with and without recurrent 
parasitaemia at day 28 of follow-up after treatment with ASAQ.   
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Figure 24: Association of low day 7 concentration with parasite 
recurrence by day 42.  
(a) lumefantrine day 7 concentration is associated with parasite recurrence at 
day 42 of follow-up after treatment with AL. (b) DEAQ concentration at day 7 
is not associated with parasite recurrence at day 42 of follow-up after 
treatment with ASAQ 
 
 
3.5.2.  Relationship between lumefantrine and N-desethylamodiaquine concentration 
with treatment response at day 28 by age group 
In my study, I found an increase in the proportion of patients without 
subsequent episode at day 28 of follow-up with age in AL group but not in ASAQ 
group. I also found an increase in the day 7 concentration of lumefantrine with age. 
Figure 25 shows collinearity between lumefantrine concentration and the proportion 
of patients without subsequent episode at day 28 of follow-up, the lower the 
proportion of patients without subsequent episode at day 28, the lower lumefantrine 
day 7 concentrations.  
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When I looked at the distribution of lumefantrine day 7 concentration by sex 
and age group, I found a lower concentration in under five years old’ girls’ patients. 
The median concentration was statistically lower in under five years’ girls’ patients 
than boys’ p = 0.0018 (Figure 26).  
 
 
 
Figure 25: Collinearity between lumefantrine day 7 concentration and 
proportion of patients without subsequent episode at day 28 of follow-up 
after treatment with artemether-lumefantrine.   
While, there was no relationship between DEAQ day 7 concentration and 
proportion of patients without subsequent episode at day 28 after treatment 
with ASAQ. (Black) line with interquartile range represents the drugs 
concentration (for lumefantrine in AL arm and for DEAQ in ASAQ arm). 
(Green) filled columns represent the proportion of patients without subsequent 
episode at day 28 in AL and ASAQ arms respectively. 
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Figure 26: Low day 7 lumefantrine concentration in girls under five year 
of age.  
(Blue) color represents male patients. There was no concentration difference 
by sex in higher age groups. (Red) color is for female. (Lines) represent 
concentration with interquartile range. (Columns) represent proportion of 
patient without recurrent parasite at day 28.      
 
 
3.5.3.  Lumefantrine day 7 concentration in under five years’ children was too low 
for post-treatment prophylaxis  
Lumefantrine day 7 concentration in under five years’ age group was lower 
for protection against new infection at day 28 of follow-up. Except, in under five 
years age group, I found a statistically significant association between lumefantrine 
day 7 concentration and protection from recurrent parasite by day 28 in the other age 
groups. These associations were still present after normalization of the concentration 
per dose and body weight in one hand, and on another hand, they were still significant 
after adjusting for covariates by multiples episodes and multiples variables, Cox 
regression model. The association between lumefantrine day 7 concentration and 
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protection from recurrence by day 28 was stronger as the age increase (Cox regression 
model, HR = 0.999, 95% CI: [0.997 – 1.000], p = 0.228 for children less than five 
years old, HR = 0.998, 95% CI: [0.997 – 0.999], p = 0.028 for age group 5 - <10 
years, HR = 0.996, 95% CI: [0.993 – 0.998], p = 0.003 for age group 10 - <15 years, 
and HR = 0.996, 95% CI: [0.994 – 0.998], p = 0.001 for age group higher or equal to 
15 years, after adjusting for site, age in each group, transmission season at inclusion 
and initial parasite count before treatment).  
As shown in Figure 27, the best lumefantrine day 7 concentration cut-off for 
prediction of parasite recurrence before day 28 was 381 ng/mg with a sensitivity and 
specificity of 52.42% and 56.70% respectively. Because of this low sensitivity and 
specificity, I look at the cut-off by age group. I found an improvement in the 
sensitivity and specificity as the age increase (Figure 28), with the best sensitivity and 
specificity in higher age group (more than 15 years).    
 
 
Figure 27: Lumefantrine day 7 concentration threshold for 
prediction of parasite recurrence at 28 days of follow-up 
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Figure 28: Lumefantrine day 7 concentration threshold for prediction of parasite 
recurrence at 28 days of follow-up by age group.  
Lumefantrine day 7 concentration in under 5 years’ patients is too low to protect them 
against parasite recurrence by day 28 of follow-up. The sensitivity and specificity for 
prediction of parasite recurrence by day 28 with lumefantrine day 7 concentration 
threshold improved as the age increase, with the best sensitivity and specificity in age 
group higher or equal to 15 years. 
 
 
3.5.4.  Multivariable and multivariate analysis of factors associated with parasite 
recurrence  
In the AL arm, lumefantrine day 7 concentration was significantly associated 
with protection against recurrent parasite by day 28 and 42 after univariate and 
multivariate Cox modelling analysis and after adjustment for significant cofactors 
(site, age, season at inclusion and initial parasitaemia). The extent of the implication 
of lumefantrine day 7 concentrations in protection against recurrence decreased from 
day 28 to day 42 and disappeared after 42. At day 63 there was no association 
between lumefantrine day 7 concentrations and protection against recurrence. By day 
28 each increase of the natural log of the lumefantrine day 7 concentration had about 
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40% lower hazard rate to have recurrence while by day 42 each increase of the natural 
log of the lumefantrine day 7 concentration had about 21% less likely to have a 
recurrence in Cox multivariable multivariate modelling (Table 21 and 23).  
In the ASAQ arm, DEAQ day 7 concentration was not associated with parasite 
recurrence by day 28 after univariate analysis at episode 1. However, it was 
associated with parasite recurrence after multivariate analysis. These associations 
disappeared by day 42 of follow-up (Table 22 and 24). The observed association after 
multivariate Cox regression analysis may be due to the accumulation of DEAQ in the 
study population after subsequent treatment during 45 days.  
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Table 21: Cox univariate and multivariate modelling of factors associated with 
risk of parasite recurrence by day 28 in AL arm (n = number of recurrence; N = total 
number of episodes) 
 
 
Table 21 continues on next page  
 
 
 
Variable Failure by day 28 (n/N) HR (95% CI) p- value 
Univariate model    
For episode 1    
Lumefantrine concentration (natural log) 74/577 0.523 (0.417 – 0.656) <0.001 
Study site    
          Sotuba 17/258 (ref)  
          Bougoula 26/213 1.855 (1.018 – 3.383) 0.044 
          Kollé 37/199 2.883 (1.644 – 5.053) <0.001 
Age 80/670 0.908 (0.871 – 0.945) <0.001 
Season at inclusion   <0.001 
          December - May (low transmission) 0/92 (ref)  
          June - November (high transmission) 80/578 3.36 1016  
Sex    0.916 
          Male 44/374 (ref)  
          Female 36/296 1.023 (0.667 – 1.569)  
Pf day 0 parasitaemia (log10) 80/670 2.020 (1.310 – 3.113) 0.001 
Day 0 temperature 80/670 1.037 (0.861 – 1.248) 0.702 
For multiple episodes    
Lumefantrine concentration (natural log) 132/1075 0.516 (0.437 – 0.608) <0.001 
Study site    
          Sotuba 24/475 (ref)  
          Bougoula 104/722 2.86 (1.790 – 4.561) <0.001 
          Kollé 75/421 3.634 (2.278 – 5.798) <0.001 
Age 203/1618 0.894 (0.867 – 0.922) <0.001 
Season at inclusion   <0.001 
          December - May (low transmission) 1/233 (ref)  
          June - November (high transmission) 202/1385 35.61 (5.11 – 248.17)  
Sex   0.836 
          Male 116/914 (ref)  
          Female  87/704 0.969 (0.719 – 1.305)  
Pf day 0 parasitaemia (log10) 203/1618 1.593 (1.268 – 2.000) <0.001 
Day 0 temperature 203/1618 1.031 (0.919 – 1.157) 0.597 
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Table 21 continues 
 
 
 
 
 
 
 
 
 
  
Multivariable model    
For episode 1    
Lumefantrine concentration (natural log) 74/577 0.636 (0.493 – 0.820) <0.001 
Study site    
           Sotuba 17/220 (ref)  
           Bougoula 25/190 1.682 (0.914 – 3.098) 0.095 
           Kollé 32/167 1.824 (1.008 – 3.299) 0.045 
Age 74/577 0.955 (0.920 – 0.991) 0.012 
Season at inclusion   <0.001 
           December - May (low transmission) 0/63 (ref)  
           June - November (high transmission) 74/514 3.12 1015  
Pf day 0 parasitaemia (log10) 74/577 1.458 (0.964 – 2.205) 0.074 
For multiple episodes    
Lumefantrine concentration (natural log) 132/1075 0.607 (0.499 – 0.739) <0.001 
Study site    
          Sotuba 22/348 (ref)  
          Bougoula 47/399 1.691 (1.011 – 2.829) 0.042 
          Kollé 63/328 2.104 (1.273 – 3.475) 0.004 
Age  132/1075 0.946 (0.914 – 0.979) <0.001 
Season at inclusion   <0.001 
          December - May (low transmission) 0/146 (ref)  
          June - November (high transmission) 132/929 5.20 1014  
Pf day 0 parasitaemia (log10) 132/1075 1.178 (0.912 – 1.521) 0.209 
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Table 22: Cox univariate and multivariate modelling of factors associated with 
risk of parasite recurrence by day 28 in ASAQ arm (n = number of recurrence; N = 
total number of episodes) 
Variable Failure by day 28 (n/N) HR (95% CI) P value 
Univariate model    
For episode 1    
DEAQ concentration (ng/ml) 10/151 0.988 (0.967 – 1.009) 0.282 
Age 10/224 1.025 (0.873 – 1.202) 0.764 
Season at inclusion   0.017 
          December - May (low transmission) 1/128 (ref)  
          June - November (high transmission) 9/96 12.20 (1.561 –95.37)  
Sex   0.280 
          Male 7/119 (ref)  
          Female  3/105 0.479 (0.126 – 1.818)  
Pf day 0 initial parasitaemia (log10) 10/224 1.917 (0.946 – 3.885) 0.071 
Day 0 temperature 10/224 0.898 (0.529 – 1.525) 0.691 
For multiple episodes    
DEAQ concentration (ng/ml) 64/740 0.992 (0.987 – 0.999) 0.026 
Age  77/1002 0.928 (0.861 – 0.999) 0.048 
Season at inclusion   <0.001 
          December - May (low transmission) 6/246 (ref)  
          June - November (high transmission) 71/756 3.971 (1.835 – 8.593)  
Sex   0.014 
          Male 56/567 (ref)  
          Female  21/435 0.482 (0.270 – 0.862)  
Pf day 0 initial parasitaemia (log10) 77/1002 0.895 (0.738 – 1.086) 0.262 
Day 0 temperature 77/1002 0.788 (0.648 – 0.959) 0.018 
    
Multivariable model    
For multiple episodes    
DEAQ concentration (ng/ml) 64/740 0.992 (0.986 – 0.998) 0.011 
Age  64/740 0.918 (0.845 – 0.998) 0.046 
Season at inclusion   0.013 
          December-May (low transmission 5/149 (ref)  
          June-November (high transmission) 59/591 3.047 (1.305 – 7.113)  
Sex    0.064 
          Male 45/432 (ref)  
          Female  19/308 0.569 (0.312 – 1.037)  
Pf day 0 parasitaemia (log10) 64/740 0.884 (0.684 – 1.141) 0.343 
Day 0 temperature 64/740 0.789 (0.610 – 1.022) 0.070 
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Table 23: Cox univariate and multivariate modelling of factors associated with 
risk of parasite recurrence by day 42 in AL arm (n = number of recurrence; N = total 
number of episodes; ref = reference) 
Variable Failure by day 42 
(n/N) 
HR (95% CI) P value 
Univariate model    
For episode 1    
Lumefantrine concentration (natural log) 173/577 0.667 (0.550 – 0.810) <0.001 
Study site    
          Sotuba 34/258 (ref)  
          Bougoula 69/213 2.681 (1.785 – 4.025) <0.001 
          Kollé 84/199 3.715 (2.507 – 5.506) <0.001 
Age 187/670 0.941 (0.915 – 0.967) <0.001 
Season at inclusion   <0.001 
          December - May (low transmission) 2/92 (ref)  
         June - November (high transmission) 185/578 17.05 (4.263 – 68.19)  
Sex    0.892 
          Male 103/374 (ref)  
          Female  84/296 1.019 (0.769 – 1.351)  
Pf day 0 parasitaemia (log10) 187/670 1.432 (1.152 – 1.781) 0.001 
Day 0 temperature 187/670 1.007 (0.889 – 1.141) 0.908 
For multiple episodes    
Lumefantrine concentration (natural log) 302/1075 0.690 (0.595 – 0.800) <0.001 
Study site    
          Sotuba 54/475 (ref)  
          Bougoula 222/722 2.937 (2.163 – 3.987) <0.001 
          Kollé 182/421 4.435 (3.274 – 6.008) <0.001 
Age 458/1618 0.936 (0.913 – 0.959) <0.001 
Season at inclusion   <0.001 
          December - May (low transmission) 12/233 (ref)  
          June-November (high transmission) 446/1385 7.361 (3.323 – 16.31)  
Sex    0.901 
          Male 256/914 (ref)  
          Female  202/704 1.013 (0.823 – 1.247)  
Pf day 0 parasitaemia (log10) 458/1618 1.336 (1.175 – 1.520) <0.001 
Day 0 temperature 458/1618 1.021 (0.937 – 1.112) 0.633 
 
Table 23 continues on next page  
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Table 23 continues 
Multivariable model    
For episode 1    
Lumefantrine concentration (natural log) 173/577 0.792 (0.643 – 0.976) 0.029 
Study site    
          Sotuba 33/220 (ref)  
          Bougoula 63/190 2.755 (1.815 – 4.183) <0.001 
          Kollé 77/167 3.042 (2.021 – 4.579) <0.001 
Age  173/577 0.976 (0953 – 1.000) 0.051 
Season at inclusion   0.002 
          December - May (low transmission) 1/63 (ref)  
          June - November (high transmission) 172/514 23.31 (3.269 – 166.2)  
Pf day 0 parasitaemia (log10) 173/577 1.161 (0.935 – 1.441) 0.176 
For multiple episodes    
Lumefantrine concentration (natural log) 302/1075 0.797 (0.677 – 0.938) 0.006 
Study site    
          Sotuba 43/348 (ref)  
          Bougoula 107/399 2.575 (1.819 – 3.646) <0.001 
          Kollé 152/328 3.761 (2.671 – 5.295) <0.001 
Age 302/1075 0.974 (0.948 – 1.000) 0.058 
Season at inclusion   <0.001 
          December-May (low transmission) 5/146 (ref)  
          June-November (high transmission) 297/929 51.17 (7.097 – 368.9)  
Pf day 0 parasitaemia (log10) 302/1075 1.090 (0.944 – 1.259) 0.238 
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Table 24: Cox univariate and multivariate modelling of factors associated with 
risk of parasite recurrence by day 42 in ASAQ arm (n = number of recurrence; N = 
total number of episodes) 
Variable 
Failure by day 
42 (n/N) 
HR (95% CI) P value 
Univariate model    
For episodes 1    
DEAQ concentration (ng/ml) 42/151 0.995 (0.987 – 1.004) 0.295 
Age 44/224 1.006 (0.933 – 1.083) 0.881 
Season at inclusion   <0.001 
          December - May (low transmission) 14/128 (ref)  
          June - November (high transmission) 30/96 3.326 (1.805 – 6.130)  
Sex    0.748 
          Male 24/119 (ref)  
          Female  20/105 0.909 (0.511 – 1.619)  
Pf day 0 initial parasitaemia (log10) 44/224 1.259 (0.932 – 1.702) 0.134 
Day 0 temperature 44/224 1.014 (0.793 – 1.296) 0.919 
For multiple episodes    
DEAQ concentration (ng/ml) 235/741 1.000 (0.998 – 1.002) 0.773 
Age 293/1002 0.971 (0.933 – 1.012) 0.169 
Season at inclusion   <0.001 
          December - May (low transmission) 22/246 (ref)  
          June - November (high transmission) 271/756 4.754 (3.114 – 7.256)  
Sex    0.009 
          Male 187/567 (ref)  
          Female  106/435 0.690 (0.523 – 0.910)  
Pf day 0 initial parasitaemia (log10) 293/1002 0.994 (0.888 – 1.114) 0.926 
Day 0 temperature 293/1002 0.868 (0.784 – 0.962) 0.007 
    
Multivariable model    
For multiple episodes    
Season at inclusion   <0.001 
          December - May (low transmission) 22/246 (ref)  
          June-November (high transmission) 271/756 4.744 (3.094 – 7.275)  
Sex    0.005 
          Male 187/567 (ref)  
          Female  106/435 0.677 (0.517 – 0.887)  
Day 0 temperature 293/1002 0.868 (0.786 – 0.959) 0.005 
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3.5.5. N-desethylamodiaquine day 7 concentration was positively correlated with 
adverse events 
The effects of day 7 concentration of lumefantrine and DEAQ on measures of 
hepatotoxicity and cardiotoxicity was assessed.  
The change in Fridericia-corrected QTc from day 0 (before treatment) to day 2 
(4 to 6 hours after the last dose) was positively correlated with DEAQ concentration. 
As this change increased, the concentration of DEAQ increased too as shown on 
(Figure 29. b). The correlation was statistically significant p < 0.001.  
For lumefantrine, the correlation was not statistically significant even if there 
is a trend (Figure 29. a). 
To consolidate this implication of DEAQ day 7 concentration in QTc 
prolongation, I also looked at the median change in different categories of patients 
according to the time of retreatment. As DEAQ accumulates in the study population 
when patients received a subsequent treatment between 26 – 45 days, the median 
change of QTc was higher in patients receiving a subsequent treatment between 26 – 
45 days (median (IQR) 18 (3 – 32.25) and mean (95% CI) 17.12 (14.51 – 19.74)) 
compared to patients at first episode (median (IQR) 12.5 (-1 – 30) mean (95% CI) 
12.52 (9.08 – 16.07)) or patients receiving subsequent treatment after 45 days (median 
(IQR) 10 (-5 – 24) and mean (95% CI) 9.62 (7.35 – 11.89)) (Kruskal-Wallis’ P < 
0.0001). Following the same line, when I considered QTc change higher than 30 
milliseconds as abnormal, I found a higher proportion of abnormal QTc in patients 
receiving subsequent treatment of ASAQ between 26 – 45 days (Pearson’s p = 0.004) 
(Figure 30. b). 
In the AL arm, there was no correlation between median QTc change and 
lumefantrine day 7 concentration. There was also no association between median QTc 
change and time frame of AL ingestion. The median change of QTc in patients 
receiving a subsequent treatment between 26 – 45 days was (median (IQR) 6 (-5.25 – 
20.00) and mean (95% CI) 6.97 (4.59 – 9.34)) compared to patients at first episode 
(median (IQR) 6 (-9 – 21) mean (95% CI) 6.4 (4.44 – 8.36)) or patients receiving 
subsequent treatment after 45 days (median (IQR) 5 (-11 – 20.75) and mean (95% CI) 
5.24 (3.23 – 7.25))  (Kruskal-Wallis’ P = 0.5041). There was also no difference in 
abnormal QTc proportion among patients receiving subsequent dose of AL between 
26 -45 days compared to the others (Pearson’s P = 0.630) (Figure 30 a)     
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Figure 29: Positive correlation between drugs concentration QTc change. 
 No correlation with lumefantrine day 7 concentration (a), positive correlation 
with DEAQ day 7 concentration (b). QTc change represents change in QTc 
value from day 0 (before treatment) to day 2 (4 to 6 hours after the last dose), 
at each episode 
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Figure 30: Median QTc change and proportion of QTc change higher 
than 30 ms in each treatment arm.  
Median QTc change was higher in patients receiving subsequent treatment of 
ASAQ between 26 and 45 days compared to QTc change at first episode or 
QTc change in patients receiving subsequent treatment after 45 days (Kruskal-
Wallis’ P < 0.0001). In AL arm there was no difference (Kruskal-Wallis’ P = 
0.5041). The proportion of patients with QTc change > 30 ms was higher in 
patients receiving subsequent ASAQ treatment between 26 – 45 days 
compared to patients at first episode or patients receiving subsequent 
treatment after 45 days (Pearson’s P = 0.004). In AL arm there was no 
difference (Pearson’s P = 0.630). QTc change represents change in QTc value 
from day 0 (before treatment) to day 2 (4 to 6 hours after the last dose) at each 
episode 
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The second adverse event of interest I looked at was day 7 concentration of 
lumefantrine and DEAQ on alanine aminotransferase change. This change was 
defined as the ALAT change from day 0 before treatment to day 3. There was a 
statistically significant positive correlation between this change and day 7 
concentration of lumefantrine (P = 0.010) and DEAQ (P = 0.0198) (Figure 31).  
These implications were reinforced when I considered outputs in Table 25 for 
DEAQ but not for lumefantrine. Patients, who received the subsequent treatment of 
ASAQ between 26 and 45 days and having abnormal ALAT at day 3 had a higher day 
7 concentration of DEAQ compared to others categories (Chi2 = 37.831, P = 0.0001). 
In AL arm, lumefantrine day 7 concentration didn’t vary significantly between 
different categories. 
 
 
 
 
Figure 31: Positive correlation between day 7 drugs concentration and ALAT 
change.  
(a) lumefantrine, (b) DEAQ. ALAT change represents change in ALAT value from 
day 0 (before treatment) to day 3 (one day after the last dose) 
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Table 25: Effect of day 7 concentration on ALAT. Patients, who received a 
subsequent treatment of ASAQ between 26 – 45 days and had elevated ALAT had a 
higher day 7 concentration of DEAQ when compared to other categories. There was 
no difference between lumefantrine day 7 concentrations by ALAT and treatment 
period categories. E1 represents initial treatment at first episode, (26 – 45 days) 
represents patients who received a subsequent treatment between 26 and 45 days, and 
(>45 days) represents patients who received subsequent treatment after 45 days. 
 
 
 
 
 
Category  Artemether-lumefantrine Artesunate-amodiaquine 
ALAT status - subsequent 
treatment period 
N 
Day 7 lumefantrine 
median (IQR) in ng/ml 
n 
Day 7 DEAQ median 
(IQR) in ng/ml 
Normal ALAT – E1 534 487.1 (309.8 – 704,8) 141 71.5 (57.1 – 93.3) 
Normal ALAT – (26 – 45 days) 181 524.3 (346.5 – 781.5) 220 91.9 (70.1 – 115. 6) 
Normal ALAT – (>45 days) 293 483.6 (295.8 – 685.7) 323 74.5 (54.2 – 98.9) 
Abnormal ALAT – E1 16 423.6 (198.4 – 788.1) 0 - 
Abnormal ALAT – (26 – 45 
days) 
2 810.7 (668.2 – 953.3) 6 112.5 (95.2 – 121.8) 
Abnormal ALAT – (>45 days) 5 459.0 (86.5 – 566.3) 16 96.1 (79.0 – 117.8) 
Total 1031 Chi2 = 9.065    P = 0.1065 706 Chi2 = 37.831   p = 0.0001 
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4 Discussion 
My study shows the implication of day 7 concentrations of lumefantrine, and 
desethylamodiaquine, in parasite recurrence and drug-related safety after repeated 
treatment with the same ACT during a period of two years of follow-up 
The major finding of this study was the accumulation of DEAQ after 
retreating with ASAQ over a short period (26 to 45 days) in the study population. The 
study population was consisted of all of the population of the study sites with 
microscopically confirmed acute, uncomplicated Plasmodium sp malaria. 
Accumulation of DEAQ had safety implications in that it was associated with an 
increase in the incidence of adverse events. A second major finding was that day 7 
DEAQ concentration was not associated with treatment outcome, which compared to 
findings with lumefantrine. A third major finding was confirmation, in a large sample 
size spanning all of the age groups (< 5 and ≥ 5 years), of the strong and independent 
effect of lumefantrine day 7 concentrations on protection from new malaria infection 
by day 28. This independent effect of lumefantrine day 7 concentration on parasite 
recurrence was still present at day 42 but was less pronounced when compared to the 
protective effect observed at day 28. The effect was not detectable at day 63. The 
protection observed was lumefantrine concentration dependent; with concentrations 
below 381 ng/ml proving not effective against subsequent infection by day 28. The 
majority of lumefantrine concentrations in children aged <5 years (60%) was below 
this 381 ng/ml protective threshold, explaining at least in part why lumefantrine day 7 
concentrations in patients in this age group did not reflect the findings of a protective 
effect observed at day 28 in older patients.   
 Clinical study findings 
Patients aged 5 to 9 years old were the most represented age group in the 
DHA-PPQ, ASAQ and AL groups, comprising 42.19%, 52.23%, and 33.98% of each 
treatment arm, respectively.  
In the PA arm, 35.19% of the participants were ≥14 years; due to the fact that 
randomization of this treatment arm was initiated in adult patients. Children were 
included in this treatment arm after an interim analysis. The proportion of adult 
patients was also high in the AL arm (27.42%), which served as the comparison group 
for the PA arm. Except for the DHA-PPQ arm, where the sex ratio was around one, a 
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lower proportion of female compared to male participants were included in the PA, 
ASAQ and AL arms. 
The results of this study showed that after approximately 10 years of use in 
Mali, ACTs are still almost 100% efficacious based on molecular correction against 
reinfection in this test study population. This finding is in agreement with previous 
studies, reporting an efficacy ≥95% at day 28 of follow-up [104-106, 294]. The focus 
of this study when compared to others was the repeated treatment for subsequent 
episodes of malaria with the same drug over a two-year period without age restriction. 
The ACTs used (DHA-PPQ, PA, ASAQ and AL) conserved their efficacy by day 28 
after molecular correction against reinfection and after treatment of subsequent 
episodes with the same drug over the two year study period. In contrast to South-
Asian countries where resistance to artemisinin and its derivatives and in some cases 
to their partner drugs is increasing, in Africa, particularly in West Africa there is no 
resistance to ACTs. It is already known that resistance to both CQ and sulfadoxine-
pyrimethamine spread from Southeast Asia to Africa, occurring first in East Africa 
before reaching West Africa. There is a concern that ACT resistance will also display 
the same pattern of spread. Fortunately, to date there is no clear sign of ACT 
resistance in East Africa. Reassuring data from Uganda demonstrated that repeat 
treatment with the same drug in young children [295] was associated with a high 
efficacy of AL and DHA-PPQ with low numbers of recrudescence cases by day 28. In 
the study reported in this thesis, the number of recrudescence cases was also very low 
with only 3 and 7 cases reported in the PA and AL arms, respectively. 
Exploring the function of the partner drugs of artemisinin and its derivatives in 
protecting against early reinfection or recurrence, I studied the parasite recurrence by 
day 28 or 42. I found that recurrence rate was higher in AL and ASAQ arm than 
DHA-PPQ and PA. Of note, the DHA-PPQ arm was the only arm that exhibited a 
lower rate of recurrent parasites by day 28 or 42. This finding was in agreement with 
previous studies showing a lower proportion of recurrence with DHA-PPQ compared 
to AL or ASAQ. This lower proportion of recurrence by day 28 or 42 with DHA-PPQ 
may be explained by the long half-life of piperaquine, which is around 4 weeks. After 
complete elimination of piperaquine from the blood or a reduction in concentration 
below its minimal inhibitory concentration, the recurrence of parasites in DHA-PPQ 
increased and reached the same levels as in the other treatment arms. It seems that 
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piperaquine, during its post-treatment prophylactic period, does not eliminate 
parasites so much as delay their rapid reappearance.   
The high recurrence level observed by day 28 or 42 in each treatment arm may 
also be explained by the endemicity of malaria in study sites. Regardless of treatment 
arm, Sotuba, which is the peri-urban village of Bamako the capital city of Mali, with 
its low endemicity (malaria exposure), had the lower proportion of parasite recurrence 
by day 28 or 42 as compared to Bougoula-Hameau and Kollé. Other factors which 
played a role in parasite recurrence were the season at time of study inclusion and the 
patient’s age. The level of recurrence by day 28 or 42 was lower during the dry season 
(December – May) in each treatment arm regardless of the site when compared to the 
high transmission season (June – November). During the dry season malaria exposure 
is very low. Similar observations were reported by Sagara et al. in Bougoula Hameau 
between 2005 to 2007 [104]. These authors found a seasonal variation in the parasite 
recurrence after treatment with ACTs with lower recurrence by day 28 recorded 
during the dry season (January – March).                 
The safety profile of different treatment arms was evaluated by examining the 
drug’s effects on the liver function and the heart. For the liver function test, it was 
found that the level of abnormal ALAT was two times higher in PA arm as compared 
to the other treatment arm. This observation was previously described in another 
report, where they found a four-fold rise in the occurrence of ALAT and ASAT grade 
3 or 4 toxicity in PA arm as compared to other ACTs[296]. In my study, PA was re-
administered to more than 67% of the patients, among which some received it 9 times 
during the two-year follow-up period. However, an interim analysis on PA re-
treatment did not find any difference in the level of hepatotoxicity between initial 
treatment and re-treatment group [105]. These ALAT elevations were transient, 
without clinical manifestations and became normal before the end of the 28 days’ 
follow-up. 
In the ASAQ arm, I found the lowest rate of abnormal ALAT. I can explain 
this by the age of the participants in this treatment arm. Hepatotoxicity due to AQ has 
generally been described in adult’s patients and after its use in prophylaxis [140, 297, 
298]. In children, most of the studies did not find any hepatotoxicity after treatment 
with ASAQ [299, 300].          
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The second adverse event analysed during this sub-study was the 
cardiotoxicity through the measurement of QTc. Almost one-third of patients in 
DHA-PPQ arm experienced some QTc lengthening defined as a QTc’s change from 
day 0 to day 2 above than 30 ms. In ASAQ arm the proportion of patient with QTc 
prolongation was 22.05%. AL and PA had lower proportions with respectively 
12.74% and 8.60%. These finding corroborate with published data. These QTc 
prolongations were transient without clinical signs. Quinoline antimalarial drugs are 
known to have an impact on QT interval; some prolong the QRS wave while others 
prolong JT or both. Quinidine, the diastereoisomer of quinine is an example of drugs 
prolonging the QT interval [301]. The second antimalarial drug inducing a QT 
prolongation associated sometimes with torsades de pointes is Halofantrine [302, 
303]. Both contain the quinoline moiety like piperaquine, which is a bisquinoline and 
AQ. The high proportion of QTc prolongation in DHA-PPQ arm compared to ASAQ 
arm may be due to the presence of two quinoline moieties in piperaquine. Other 
similar studies showed a significant lengthening of the mean QTc in DHA-PPQ arm 
but without significant cardiac effects [304, 305] 
Many factors can affect QT interval, among which malaria status, age, gender, 
electrolytes concentrations and some classes of drugs[306]. The contribution of these 
factors is minimised by randomization of treatment arms.  
Pharmacokinetic and pharmacodynamics 
To study the relationship between in vivo results (efficacy and safety) and 
drug concentration, we developed and validated or revalidated high performance 
liquid chromatographic methods to quantify lumefantrine and DEAQ in plasma 
collected from uncomplicated malaria patients treated with AL or ASAQ. The 
analytical methods developed were able to quantify day 7 concentration of 
lumefantrine and DEAQ in plasma accurately.  
For pyronaridine, the quantification method developed and validated had a  
low limit of quantification set at 25 ng/ml and a limit of detection of 7 ng/ml, and was 
not able to quantify drug concentration in malaria patients’ plasma sample, 4 days 
after the last dose. In the literature, pyronaridine day 7 concentration in whole blood 
was estimated to be around 37 ng/ml[307, 308]. Moreover, some studies, most often 
in rabbits showed that pyronaridine concentrates in blood cells, with blood: plasma 
ratio varying from 4.9 to 17.8 in rabbits [161, 164].  
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For lumefantrine quantification, the LLOQ (20 ng/ml) was far lower than the 
mean concentration of this drug in plasma at day 7 [207, 309].  
The methods for lumefantrine and DEAQ quantification were sensitive, 
specific, reproducible, and accurate. They have been validated according to FDA 
guidance. Moreover, the accuracies and coefficients of variation obtained with the 
QCs samples during patients’ samples analysis (Table 17) showed that it is a good 
method for clinical studies. 
The DEAQ method of detection was fully revalidated. It was a sensitive, 
specific, reproducible, and accurate method for quantification of DEAQ in plasma. 
The LLOQ set at 24 ng/ml showed that the method was sensitive to quantify DEAQ 
in patients’ samples at day 7 of follow-up (4 days after the last dose). The median day 
7 plasma concentration of DEAQ in African children with malaria treated with ASAQ 
is estimated to be around 91.5 ng/ml [144], which is far higher than the LLOQ of my 
method. As shown by the accuracy and coefficient of variation of QCs samples during 
patients’ samples analysis (Table 18), it is a good method for clinical studies. 
The methods I developed and validated to quantify lumefantrine, DEAQ and 
pyronaridine in human plasma gave excellent linearity. Calibrations curve’s 
coefficients of correlation were always higher than 0.997 (Figure 17). 
The internal standards used (TA3099 for lumefantrine and (4-((7-chloro-4-
quinolinyl) amino)-1-Pentanol) for DEAQ and pyronaridine) are structurally related 
to the drugs and are not usually found in patients’ blood. Because they are not drugs 
to treat any human diseases, this makes them appropriate for quantification. They also 
did not interfere with any other peaks coming from endogenous or concomitant 
treatment or any other antimalarial drugs. They had a good extraction recovery more 
than 75% and stable in the analytical conditions.        
I found a high inter-individual variability in day 7 plasma concentration of 
lumefantrine and DEAQ. The median lumefantrine day 7 concentration with 
interquartile range at first episode was 477 (304.7 to 701) ng/ml (mean (SD) = 
543.1(329.1)), for DEAQ it was 71.3 (57.1 to 93.3) ng/ml (mean (SD) = 88.8 (65.2) 
ng/ml). These concentrations were comparable to data published elsewhere [310]. 
During the two years period of follow-up of this study, some patients suffered more 
than 10 episodes of uncomplicated malaria, and they always received the same 
treatment if the time period between the following episodes was equal or superior to 
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28 days. When I compared day 7 drug concentrations between episodes, I found 
similar concentration between the different episodes. I did not find any increase in 
lumefantrine or DEAQ day 7 concentration episode by episode. However, when I 
compared the concentration of the drug at episode 1 to its concentration in patients 
who received a subsequent treatment, I found a high concentration of DEAQ in 
patients who received a subsequent treatment between 26 and 44 days (p < 0.0001). 
This finding suggests that, when patients received a second treatment with ASAQ in a 
period between 26 to 44 days, there will be an accumulation of DEAQ in those 
patients’ blood (Figure 19 b). I did not find any accumulation of lumefantrine in my 
study population regardless of the time of the subsequent treatment after 26 days of 
the precedent treatment. This accumulation of DEAQ in study population has to be 
considered in places where AQ is use in IPTi and SMC[8]. If DEAQ is involved in 
any of the adverse events (cytotoxicity, hepatotoxicity or cardiotoxicity)[311, 312], 
this accumulation may exacerbate it. 
Lumefantrine day 7 concentration increases with age in my study population. I 
found a high day 7 concentration of lumefantrine in above 15 years’ age group. The 
concentration I found in this age group was comparable to the concentration found in 
10 - <15 years age group but higher than the concentration in 5 - <10 and under five 
years’ age group (p < 0.0001). The lower lumefantrine day 7 concentration was 
recorded in under five year’s age group. This profile of lumefantrine day 7 
concentration may be explained by the activity of the CYP3A4, which is the primary 
enzyme implicated in lumefantrine metabolism. This CYP3A4 is more active in 1 to 
12 years old children than adult [184, 313, 314]. My findings is in agreement with 
other studies indicating an increase of lumefantrine disposition with age [207]. Unlike 
lumefantrine, DEAQ concentration didn’t exhibit any correlation with age group (p = 
0.1803).  
Lumefantrine day 7 concentration varied also significantly between sexes. It 
was lower in female patients than male (p = 0.0093). This difference was statistically 
significant between under 5 years male and female. It may also be explained by the 
expression profile of the CYP3A4, which is higher in female than in male [185]. As 
for age groups, DEAQ day 7 concentration didn’t vary significantly with sex (p = 
0.1598).  
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Both lumefantrine and DEAQ day 7 concentrations were lower in patients 
with fever (axillary temperature equal or higher than 37.5°C) at the start of the 
treatment compared to patients without fever.    
Regarding the pharmacokinetic pharmacodynamics relationship of 
lumefantrine and DEAQ on recurrent parasite or post-treatment prophylaxis after 
repetitive treatment with AL or ASAQ, I found that lumefantrine day 7 concentration 
was lower in patients with a subsequent episode of malaria by day 28 (p < 0.0001) 
and day 42 (p = 0.0102) of follow-up when compared to patients without a 
subsequent episode. The median concentration was 66 % higher (p <0.0001) in 
patients without recurrent parasite by day 28 as compared to those with recurrent 
parasitaemia. For DEAQ, there was no difference in its day 7 concentration between 
patients with or without recurrent parasite by day 28 and day 42 of follow-up. This 
implication of lumefantrine concentration in post-treatment prophylaxis is strenghten 
by its high association at day 28 of follow-up (p < 0.0001), which was diminished by 
day 42 of follow-up (p = 0.0102) and was no longer detectable at day 63. This 
association is confirmed with Cox proportional hazard multivariable and multiple 
episodes modelling, which showed good correlation between lumefantrine day 7 
concentrations and patients protection against new episode of malaria before day 28 
of follow-up. Why lumefantrine day 7 concentration impacts on parasite recurrence 
by day 28 and 42, but not DEAQ day 7 concentration? There is no clear answer to this 
question. However, a study showed that CQ (same family like AQ and DEAQ) 
efficacy is time dependent (time above minimum inhibitory concentration) [315]. If 
that apply to DEAQ, which minimum inhibitory concentration did not reach 28 days 
post treatment, may explain why its concentration at day 7 did not impact on parasite 
recurrence by 28 days of follow-up. Lumefantrine and quinine belong to the same 
family. A study showed that quinine efficacy is concentration and time dependent 
[316] and if that apply to lumefantrine, it may explain its day 7 concentrations effect 
on parasite recurrence. Low day 7 lumefantrine concentration has been involved in 
parasite recrudescence to AL [202, 203]. In my study, parasites recrudescent level 
was very low. There was no case of recrudescence in the ASAQ arm. In the AL arm, 
we found 7 cases of recrudescence. In these 7 cases, day 7 lumefantrine 
concentrations were available for 6 cases and unavailable for one case. Within the six 
available cases, a 10 year old patient did not eliminate his parasite burden. He came 
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with parasites at day 1, 2, 3, 7 and 27 of follow-up and there was no detectable 
lumefantrine in his blood at day 7 of follow-up. After investigation of this last patient, 
it was found that he was keeping drugs under his tongue and spat them out when far 
from the study team. This particular patient showed the importance of 
pharmacokinetic in monitoring drug efficacy. All patients, except one, who had 
parasite recrudescence had day 7 concentrations of lumefantrine lower than the low 
interquartile concentration.  This is in agreement with previous reported data linking 
parasite recrudescence to low lumefantrine day 7 concentration [207].    
I found collinearity between lumefantrine day 7 concentration and AL 28 days 
uncorrected efficacy by age group. The lower lumefantrine day 7 concentrations and 
the lower 28 days uncorrected efficacy rates were observed in under five years’ age 
group, and those higher were found in 15 years old and above age group. 
The lowest lumefantrine day 7 concentrations were observed in under five 
years’ female children as compared to under five years’ male children (p < 0.01). This 
difference may be explained by the high activity of the metabolism enzyme CYP3A4 
in female than male [185]. 
Lumefantrine day 7 concentration of 175 ng/ml and 280 ng/ml were used as 
cut-off values for prediction of parasite recrudescence to AL [202, 203]. In my study, 
the level of recrudescence was very low. We tried to look at these cut-off values of 
lumefantrine day 7 concentrations, which could predict parasite recurrence at day 28 
of follow-up using the receiver operating characteristic (ROC curve) statistics. 
Lumefantrine day 7 concentration threshold, which can predict parasite recurrence at 
day 28 of follow-up, was estimated to 381ng/ml with a sensitivity of 52.4% and 
specificity of 56.7%. Because of these low sensitivity and specificity, we looked at 
the threshold in age group. Sensitivity and specificity increase as age increase with 
the best sensitivity and specificity in the highest age group. This finding was 
surprising because higher age groups had high lumefantrine concentration and the 
malaria premunition should also play a role in the post-treatment prophylaxis in this 
age group in malaria endemic areas. Participants in the lower age groups should be 
those that give the best sensitivity and specificity because of their lower drug 
concentration and their lower premunition. However, it is already known that drug 
efficacy depends on the proportion of the free drug in the blood (unbound to plasma 
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proteins). It is unknown if there is a difference in the percentage of free lumefantrine 
concentration between these age groups to explain this phenomenon.  
DEAQ concentration has been shown to be associated with parasite 
recurrence. The strong association was described with day 3 concentration of DEAQ 
after treatment with AQ in monotherapy [317]. At day 3 the inter-individual 
variability was high compared to day 7, and concentration at day 3 did not correlate 
well with AUC, which is the best pharmacokinetic parameter for the determination of 
treatment outcome in uncomplicated malaria. Another study showed a weak 
association of day 7 concentration of DEAQ with parasite recurrence [318], however 
this study used a loose combination of AQ plus AS, and the majority of patients with 
recurrent parasites did not have detectable DEAQ at day 7. The authors thought that 
patients with undetectable DEAQ used AS only as monotherapy [318]. In the current 
sub-study analysis, I did not find any association between DEAQ day 7 concentration 
and parasite recurrence by day 28 or 42. This implies that, unlike for lumefantrine, 
DEAQ day 7 concentration cannot be used to predict parasite recurrence by day 28.  
Repeat treatment with ASAQ for a short period of time leads to accumulation 
of DEAQ in the study population investigated.  If DEAQ accumulation is associated 
with adverse events this may ultimately affect treatment compliance and efficacy 
therapy adherence. I found a good correlation between DEAQ day 7 concentrations 
and QTc prolongation. The effect of DEAQ day 7 concentration on QTc was mainly 
observed when I considered the QTc change from day 0 to day 2. When I used the 
absolute QTc at day2 and monitored the effect of day 7 concentration on it, I found no 
correlation between the two parameters. However, when I considered absolute QTc at 
day 2 higher than 450 ms as abnormal, the concentration of DEAQ was higher in 
patients with abnormal than normal QTc (p = 0.0182). In another hand, the change in 
QTc from day 0 to day 2 was correlated with DEAQ day 7 concentrations with a 
spearman’s correlation coefficient of 0.1647 and p < 0.001. To emphasize this 
correlation I looked at the QTc change between episode 1 treated patients, 26 to 45 
days subsequent treated patients and above 45 days subsequent treated patients. That 
was based on knowing that DEAQ concentrates in study population when patients 
receive the subsequent treatment between 26 and 45 days. I found a higher median 
change of QTc (p < 0.0001), and a higher proportion (p = 0.004) of patients with QTc 
change higher than 30 ms, in patients receiving subsequent treatment after a short 
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period as compared to episode 1 or to patients who received subsequent treatment 
after 45 days. 
AQ, like other aminoquinolines, has been shown to affect cardiac 
electrophysiology, but very few studies have investigated the concentration-dependent 
QTc prolongation of AQ or its metabolite DEAQ. Halofantrine is the only quinolone 
antimalarial for which the effects on QTc prolongation have been extensively studied 
[302, 303, 319, 320]. Other quinoline antimalarial drugs have been implicated in QTc 
prolongation, but their concentration-dependent QTc prolongation has not been fully 
characterised. 
QTc has been evaluated in many AL studies. AL was associated with a small 
increase in mean QTc (around 7.45 ms) compared to the placebo. In my study, the 
mean increase was less than 5 ms at episode 1 or at any period of subsequent 
treatment. I did not find any correlation between lumefantrine day 7 concentration and 
change in QTc from day 0 to day 2 (Spearman’s coefficient of correlation of 0.0552 
and p = 0.074). AL does not prolong the QTc.        
Another major adverse event finding was the correlation between day 7 
concentration and hepatotoxicity as measured through ALAT levels. I found a 
positive correlation between the change in ALAT value from day 0 to day 3 and day 7 
concentration of lumefantrine (Spearman’s coefficient of correlation of 0.1008 and p 
= 0.010) and DEAQ (Spearman’s coefficient of correlation of 0.0868 and p = 0.0198). 
This concentration-dependent action on ALAT change was strengthen in ASAQ arm 
by the elevated concentration of DEAQ in patients who received a subsequent 
treatment between 26 and 45 days and had abnormal ALAT at day 3 as compared to 
the others categories (p = 0.0001) (Table 25). AQ has been implicated in 
hepatotoxicity, which was linked to its metabolite quinone-immune in the absence of 
glutathione; the authors have suggested an immune-mediated idiosyncratic 
hepatotoxicity [321]. This idiosyncratic hepatotoxicity was supposed to be 
multifactorial with formation of reactive metabolite of the drug, genetic and 
environmental factors as well as drug exposure [322]. It is also known that 
glutathione decreases with ageing [323]. In my study, all of the participants in ASAQ 
arm were young children under 15 years meaning with a high glutathione 
concentration that could explain at least partly the low proportion of abnormal ALAT 
in ASAQ arm.     
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All the cases of abnormal cardiac and liver functions were resolved by day 28 
of follow-up.           
This work was part of one of the largest clinical trial on malaria, which was a 
phase IIIb/IV comparative, randomised, multi-centre, open label, parallel 3-arm 
clinical study to assess the safety and efficacy of repeated administration of 
pyronaridine-artesunate, dihydroartemisinin-piperaquine or artemether-lumefantrine 
or artesunate-amodiaquine over a two-year period in children and adult patients with 
acute uncomplicated Plasmodium sp. malaria. Data from repeat treatment episodes 
over a short period of time demonstrated the accumulation of DEAQ in this study 
population. Repeat treatment with a long follow-up period was necessary to define the 
risk of malaria exposure and parasite recurrence at an individual level based on 
patient data from a single study site in Mali. 
 
 
 
121 
 
5 Conclusion 
Repetitive treatment with ASAQ over a short period of time (between 26 and 
45 days) leads to accumulation of DEAQ, the main and active metabolite of AQ in 
this study population. The accumulation of DEAQ corresponds to an increase in the 
occurrence of adverse events like cardiotoxicity (prolongation of QTc interval) and 
hepatotoxicity (elevation of alanine aminotransferase enzyme). Contrary to 
lumefantrine concentration on day 7, DEAQ day 7 concentrations were not associated 
with treatment outcome.  
Lumefantrine day 7 concentration was strongly associated with attainment of 
protection against new Pf reinfection by day 28. However, the association decreased 
by day 42 and was no longer detectable at day 63. The effect was still present after 
normalization of lumefantrine dose and patient weight and also after adjusting for 
other significant cofactors (study site, age, season at inclusion, and initial 
parasitaemia). 
Lumefantrine day 7 concentrations lower than 381 ng/ml were not protective 
against new infection by day 28. Children aged <5 years had a low day 7 
concentration of lumefantrine compared to other age groups. AL dosage should be 
adjusted in this age group, particularly in girls who have lower lumefantrine day 7 
concentrations than boys of the same age.  
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